TW200526202A - Treating bone-related disorders with selective androgen receptor modulators - Google Patents

Abstract

This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administering a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or its analogue, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The invention also provides methods of decreasing fat mass (FM) and increasing lean mass, comprising administering same.

Description

200526202 IX. Description of the invention: c. The technical field to which the invention belongs] Field of the invention The present invention administers a therapeutically effective amount of a selective androgen 5 receptor regulator (SARM) and / or its analogs, derivatives, isoforms Structures, metabolites, pharmaceutically acceptable salts, agents, hydrates, N-oxides, or any combination thereof, provided for the treatment, prevention, suppression, suppression or reduction of a bone-related disorder such as osteoporosis Disease, osteopenia, increased osteolytic effects, fractures, weak bones, and / or reduced bone mineral density (BMD) by 10%. The present invention also provides a method for reducing fat mass (fm) and increasing lean muscle mass, which includes the same administration effect. [PRIOR ART 3 BACKGROUND OF THE INVENTION In both men and women, bone mineral density (BMD) decreases with increasing age. Bone Mineral Content (BMC) and Decreased Bone Mineral Density ΐ 'is associated with decreased bone strength and the patient's fracture factor. Osteoporosis is a systemic skeletal disease characterized by low bone and bone tissue degradation, resulting in increased bone fragility and increased likelihood of fracture. In the United States, more than 25.2 million people are affected by this condition, and 1.3 million fractures are caused each year, including 500,000 spine fractures, 250,000 hip fractures, and 24 Ten thousand wrist fractures. The most severe consequences of body fractures are osteoporosis, with 5-20% of patients dying within a year, and more than 50% of survivors becoming poorly mobile. Elderly people have the highest risk of osteoporosis, so it is expected that this problem will increase significantly with the aging of the population in 200526202. Over the next sixty years, the global incidence of bone fractures is forecast to triple; and one study estimates that 4.5 million hip fractures will occur worldwide by 2050. In view of the high incidence of osteoporosis and other osteoporosis-related disorders, bone-related osteoporosis-related disorders are also major clinical health concerns for men and women. At the basic science and clinical levels, there is an urgent need for novel methods to reduce the incidence of moonshell-related disorders. [Explanation Content ^] Summary of the Invention 10. In one embodiment, the present invention provides a method for treating a subject suffering from a bone-related disorder, the steps comprising administering a selective androgen receptor to the individual. Regulator (SARM) compounds. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or 15 N-oxide of any of the SARM compounds A composition. In another embodiment, the invention provides a method for reducing the incidence of a bone-related disorder in a subject, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate or N-oxide of the SARM compound A composition. In another embodiment, the present invention provides a method for increasing bone strength in a body, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method includes 200526202 administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate or N-oxide of a SARM compound or Ren — composition. In another embodiment, the present invention provides a method for increasing bone mass 5 of a body, which comprises administering to the individual a selective androgen regulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or N_oxide or any combination. 10 In another embodiment, the invention provides a method for reducing the incidence of bone erosions in a body, comprising administering to the individual a selective androgen receptor modulator (SARM) compound . In another embodiment, the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or team oxide of a SARM compound, or any combination thereof. Thing. In another embodiment, the present invention provides a method for reducing fat in a body comprising administering to the individual a selective androgen regulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or N-oxide of a SARM compound Any hydrazone and compound. In another embodiment, the invention provides a method for reducing the incidence of increased fat mass (FM) in a body, comprising administering to the individual a selective androgen receptor modulator (SARM) compound . In another embodiment of 200526202, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or N-oxide or any one of the SARM compounds. A composition. In another embodiment, the present invention provides a method for increasing the muscle mass of an individual, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound combination. 10 In another embodiment, the present invention provides a method for reducing the incidence of decreased muscle mass in an individual, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate or N-oxide or any of the SARM compounds A composition. In another embodiment, the present invention provides a method for increasing the mass of a person's diaphragm, which comprises administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound A composition. The drawings are briefly explained from the following detailed description together with the attached drawings, which will more fully understand and understand the present invention, in which: 200526202 Figure 1: Whole body bone mineral density (BMD) at 120 days (mean soil measurement) Standard error [SEM]). a = P &lt; 0.05 vs. control group with ovariectomy; b = P &lt; 0.05 vs. intact control group. Figure 2: Bone mineral density of the lumbar spine (L5-L6) at day 120 (average 5 standard error of soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 3: Bone mineral density of the lumbar spine (L2-L4) on day 120 (standard error of mean soil measurement). Figure 4: Bone mineral density at the 120th day of femoral zone 4 (mean standard error of 10 soil measurements). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 5: Bone mineral density of the proximal femur at 120 days (mean standard error of soil measurement). Figure 6: Cortical thickness of the central femoral shaft at day 120 (mean 15 standard error of soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 7: Cortical content of the mid-femoral diaphysis at day 120 (mean soil standard error of measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. 20 Figure 8: Periosteum perimeter of the diaphyseal shaft of the femur at day 120 (mean standard error of soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 9: Bone trabecular density of the distal femur at day 120 (mean ± standard error of measurement). a = P &lt; 0.05 relative to the control group with ovariectomy; 200526202 b = P &lt; 0.05 relative to the intact control group. Fig. 10: Maximum femoral load on day ((standard error of mean soil measurement). a = p &lt; 005 relative to the control group with resected Indian nest; bu 005 relative to the complete control. 5 Figure 11: Compressive strength of L5 spine on day 120 (standard error of mean soil measurement). Figure 12: (A) Percentage change of bone mineral content (BMC) at day 120. (B) Time history of changes in bone mineral content. Data are presented as standard errors of mean soil measurements. 10 Figure 13: Percent change in bone mineral content (BMC) at day 30 (mean standard error of soil measurement). Figure 14: Body weight at 120 days (mean ± standard error of measurement). a = P &lt; 0.05 vs. the ovariectomized control group; b = p &lt; 〇〇 ^ for the complete control group. 15 Figure 15: Fat mass percentage (mean ± standard error of measurement) at day 120. a = P &lt; 0.05 relative to the ovariectomized control group; b = p <0.05 relative to the intact control group. Figure 16: Aosteocalcin levels (standard error of mean soil measurements) at day 120. a = P &lt; 0.05 relative to the control group with ovariectomy; b = P &lt; 0.05 relative to the intact control group. Figure 17: Whole body bone mineral density on day 210 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = p &lt; 0.05 relative to the intact control group. Figure 18: Bone mineral density of the lumbar spine (L5-L6) at day 210 (flat 200526202 standard error of mean soil measurement). a = P &lt; 0.05 vs. control group with ovariectomy; b = P &lt; 0.05 vs. intact control group. The complete control group was sacrificed on day 210. Figure 19: Bone mineral density in the 4th femur zone on day 210 (mean standard error of 5 soil measurements). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. The complete control group was sacrificed on day 210. Figure 20: Cortical content of the central femoral shaft at day 210 (standard error of mean soil measurement). a = P &lt; 0.05 vs. control group of 10 ovariectomized; b = P &lt; 0.05 vs. intact control group. Figure 21: Cortical thickness of the central femoral shaft on day 210 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 22: Periosteum perimeter of the diaphyseal shaft of the femur at day 210 (mean 15 standard error of soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 23: Bone trabecular density of the distal femur at day 210 (mean ± standard error of measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. 20 Figure 24: Maximum femoral load measured by three-point bending on day 210 (mean standard error of soil measurement). a = P &lt; 0.05 relative to the control group with the ovipositor removed; b = P &lt; 0.05 relative to the intact control group. Figure 25: Body weight on day 210 (mean ± standard error of measurement). a = P &lt; 0.05 vs. control group for ovariectomy; b = P &lt; 0.05 phase 200526202 for complete control group. Brother 26 Figure · Fat mass percentage on day 210 (mean ± standard error of measurement). a = p &lt; 0.05 relative to the ovariectomized control group; b = p &lt; 0.05 relative to the intact control group. 5 Figure 27: Whole body bone mineral density at day 120. a = P &lt; 0.05 relative to the control group with ovariectomy; b = p &lt; 0.05 relative to the complete control group. Figure 28: Bone mineral density of the L5-L6 spine at day 120. a = P &lt; 05 vs. control group with ovariectomy; b = p &lt; 0.05 vs. intact 10 control group. Figure 29: Whole body bone mineral density on day 210. a = p &lt; 005 compared to the control group with ovariectomy; b = p &lt; 0.05 compared to the complete control Figure 30: Bone mineral density of L5-L6 spine at day 210. a = 15 P &lt; 0 · 05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the intact control group. Figure 31: Body weight on day 120. a = P &lt; 0_05 relative to the control group of the resected nest; b = P &lt; 0.05 relative to the intact control group. Figure 32: Weight on day 210. a = P &lt; 0.05 relative to the control group with 20 nests removed; b = P &lt; 0.05 relative to the complete control group. Figure 33. Fat mass percentage on day 120. a = p &lt; o relative to the ovariectomized control group; b = p &lt; 0.05 relative to the intact control group. Figure 34: Fat mass percentage on day 210. a = p &lt; 〇 q5 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the intact control group. 12 200526202 C Embodiment 3 Detailed Description of the Preferred Embodiments The present invention administers a selective androgen receptor modulator (SARM) compound and / or its analog, derivative, isomer, 5 Xie, pharmaceutically acceptable salts, medicaments, hydrates, N-oxides, or any combination thereof, provided in the individual for the treatment, prevention, suppression, suppression or reduction of a bone-related disorder Methods of Incidence. The present invention further provides a method for increasing the bone strength or bone mass of an individual, increasing the muscle mass of an individual, and reducing the fat mass (FM) of an individual by the same administration effect. In another embodiment, the invention provides a method for reducing the incidence of a bone-related disorder in a subject, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or N-oxide or any A composition. In another embodiment, the present invention provides a method for preventing a bone-related disorder in a subject, which comprises administering one of the aforementioned compounds. In another embodiment, the present invention provides a method for suppressing a bone-related disorder in a body, which comprises the same administration effect. In another embodiment, the present invention provides a method for inhibiting a bone-related disorder in a body, which comprises the same administration effect. In one embodiment, the bone-related disorder is osteoporosis. In another embodiment, the bone-related disorder is bone deficiency. In another implementation 13 200526202 cases, the osteoid-related disorder is an increase in osteolytic effect. In another embodiment &apos; The bone-related disorder is a fracture. In another embodiment, the bone-related disorder is bone fragility. In another embodiment, the bone-related disorder is a decrease in bone mineral density (BMD). In another embodiment, the osteogenesis related disorder is any combination of osteoporosis, osteopenia, increased osteolytic effect, fractures, bone fragility, and decreased bone mineral density (BMD). Each condition represents an individual embodiment of the invention. In one embodiment, "osteoporosis" refers to the thinning of bones and the reduction of bone mass due to the depletion of calcium and osteoprotein. In another embodiment, moonbeam osteoporosis is a systemic skeletal disease, It is characterized by low bone and bone tissue deterioration, and thus increases bone fragility and the possibility of fractures. The abnormal bone strength of osteoporosis patients results in an increased risk of fractures in one embodiment. In another embodiment In one embodiment, osteoporosis causes depletion of calcium and protein collagen commonly seen in the bone, resulting in bone marrow abnormalities or decreased bone density in one embodiment. In another embodiment, bones with osteoporosis are Fractures can usually occur without causing a slight fall or injury to the fracture. In solid towels, the fracture may be a fissure (such as in the case of a hip fracture) or a collapse (such as in a spinal compression fracture). Situation) The shape 20 = 1 vertebra and the wrist are fractures caused by osteoporosis ^ 2 see the site, although the fracture may also occur in other bone sites. In another known example, the Suppressed osteoporosis may lead to changes in posture, physiological abnormalities, and decreased mobility. Born in the embodiment, osteoporosis is caused by a lack of androgen. In another shot, osteoporosis is lack of androgen After that, 200526202 was born in another embodiment, osteoporosis is primary osteoporosis. In another example, osteoporosis is secondary osteoporosis. In another embodiment, 'osteoporosis is Postmenopausal osteoporosis. In another example, osteoporosis is juvenile-type osteoporosis. In another 5:!, Osteoporosis is spontaneous osteoporosis. In another example, the moonbeam qi, The disease is senile osteoporosis.… Exhaustive column τ, the primary osteoporosis is type 1 _ raw bowfish disease in another-solid patch, the primary osteoporosis is 10th

= Sexual osteoporosis. Each type of osteoporosis represents another embodiment of the present invention.

In another embodiment, osteoporosis and osteoporosis are systemic Yueluo disease # characterized by low f f and deterioration of the microarchitecture of bone tissue. In the first embodiment, "the deterioration of the micro-architecture refers to the thinning effect of the trabecular bone (definition = posterior) and the connection between the trabecular bones that have lost bone wealth. In another embodiment," the bone Looseness, defined as the bone mineral density _D) is more than 2.5 standard deviations lower than the average of young adults. In another embodiment, the boundary of 'osteoporosis' is that the bone mineral f content (BMC) is 2.5 standard deviations lower than the average of two young adults. In another embodiment, "osteoporosis" Department is defined as ㈣ material density is 2.0 lower than the average value of young adults; ^ quasi deviation or more. In another example, "osteoporosis, the line boundary 疋 is the average value of Θ mineral content than young adults Lower than 20 standard deviations. In another embodiment, "osteoporosis" is defined as a bone mineral shell density that is 30 standard deviations lower than the average of young adults. In another example, "osteoporosis," is defined as The bone mineral content is more than 3.0 standard deviations lower than the average of young adults in the year 15 200526202. The terms &apos; of osteoporosis or bone deficiency represent individual embodiments of the invention. In another embodiment, "" osteoporosis, "is defined as a bone mineral density that is 2.5 standard deviations lower than the average of young adults. In another embodiment 5," "osteoporosis," is defined as riding Meal content was 2.5 standard deviations lower than the average for adults. In another embodiment, "osteoporosis" is defined as a standard deviation of bone density less than 20 standard deviations from young adults. In another case, "" osteoporosis "is defined as the bone mineral beriuli is 20 standard deviations lower than the average of young adults. In another case, Shi Cai," osteoporosis ,, The line was defined as 3.0 standard deviations of bone mineral density below the average for young adults. In another embodiment, "osteoporosis" is defined as 30 standard deviations in bone mineral content below the average of young adults. The definitions of osteoporosis or osteoporosis represent individual embodiments of the invention. 15 Methods for assessing osteoporosis and osteoporosis are well known in the art. For example, in the '-embodiment, the bone mineral density of a patient is measured by density measurement and expressed in grams per square centimeter, and will be compared with "normal value," to obtain a "T score," , Where the "normal value" is the average osteoporosis f density of young adults who are gender-matched during their fistula period. In another embodiment, the amount of bone loss in a patient is the same as that of an individual of the same age: sex Compare the expected amount of churn to get "z. This is defined as "" osteoporosis "in one embodiment, which is defined as a T-score greater than the average of two standard deviations of young adults. In another embodiment," osteoporosis, "is defined as a ZC score More than 25 standard deviations below the average for young adults. 20 200526202 The average of people in the ““ Porphyria ”lineage in the“ Also ”category is more than one standard deviation. The score in the other two positive circles is 2.00 lower than the average value of young adults. In the example, "osteoporosis" is defined as τ recorded as 3._ fresh deviation lower than the average of young adults. In another example, &quot; &quot; osteoporosis &quot; is defined as a z-score that is 3.0 standard deviations below the average of young adults.

In another embodiment, "osteoporosis" is defined as a τ score 25 standard deviations lower than the average of young adults. In another embodiment, "osteoporosis, defined as z The score is 2.5 standard deviations lower than the average of young adults. In another example, "osteoporosis" is defined as a τ score 2.0 standard deviations below the average of young adults. In another embodiment,

"Osteoporosis" is expected to be a standard deviation of ζ scores compared to the average of young adults. In another embodiment, "osteoporosis" is defined as a τ score of 15 points which is 3.0 standard deviations below the average of young adults. In another embodiment, &quot; &quot; osteoporosis &quot; is defined as a Z score of 3.0 standard deviations below the average of young adults. The definitions of osteoporosis or bone f deficiency represent individual embodiments of the invention. 2 "Bone Mineral Density (BMD) ,, a term that refers to the degree of the actual bone after measurement. The absolute amount of bone measured by the bone mineral density and degree is generally related to the strength of the bone and its bearing. The ability to weigh is related. By measuring bone mineral density, it is possible to predict the risk of a fracture in one of the same ways as measuring blood pressure to help predict the risk of stroke. In embodiments, known bone minerals may be used Material Density Mapping Technique 17 200526202 technique to measure bone mineral density. In one embodiment, multiple techniques can be used to measure bone density of the hip, spine, wrist or calcaneus. The preferred method of measuring bone mineral density is double Energy X-ray Densitometry (DEXA). This technique can be used to determine bone mineral density in the hip, abdomen (AP) spine, lateral spine, and wrist. Measurements at any site can predict the overall fracture risk, but come from The information for a particular site is the best predictor of fracture at that site. Quantitative computerized tomography (QCT) can also be used to measure the bone mineral density of the spine. See, for example, Wahner HW et al. medical : Quantitative Procedures, Book B, Toronto Little, Brown &amp; Co., 1983 (see page 10107_132); J Nucl Medicine, pages 1134-1141 (1984), "Analysis of Bone Minerals 1 Part I, Ewen; j Nucl, "The Bone Mineral Density of the Radius," pp. 13-39 (1985), Ewen. Various methods for measuring bone mineral density represent individual embodiments of the present invention. In one embodiment, "bone deficiency," refers to a bone mineral density or bone 15 mineral content that is between 1 and 2.5 standard deviations lower than the average of young adults. In another embodiment, "bone deficiency , Refers to the reduction of calcification or bone density. In one embodiment, the term covers all skeletal systems that are aware of the condition. Each definition or method of diagnosis of a condition disclosed in the present invention 'represents an individual embodiment of the present invention. 20 In one embodiment, the term “fracture,” refers to a fracture of the bone, and covers both vertebral and non-vertebral fractures. In one embodiment, “the bone is weak,” refers to the weakened state of the bone, It is the prime cause of such bone fractures. In one embodiment, the osteoporosis, osteoporosis, increased osteolytic effects, fractures, weak bones, reduced bone mineral density, and other diseases or disorders of the present invention are caused by hormonal imbalance, destruction, or inability. Caused by balance. In the other-implementation of wealth, the occurrence of these conditions has nothing to do with the imbalance, destruction or imbalance of the Dutch. Various possibilities represent individual embodiments of the invention. In one embodiment, the imbalance, disruption, or imbalance of a hormone includes an excessive amount of: a hormone. In another embodiment, a hormonal imbalance, disruption or: balance includes a lack of a hormone. In one embodiment, the hormone is a steroid hormone. In another embodiment, the hormone is a kind of sakizaki. In another embodiment, the hormone is an androgen. 10 In another embodiment, the hormone is a glucocorticoid. In another embodiment, the hormone is a corticosteroid. In another embodiment, the ㈣ is a luteinizing hormone㈣. In another embodiment, the Rael elephant is a follicular hormone (FSH). In another embodiment, the hormone is any other hormone known in the art. In another embodiment, the imbalance, disruption, or imbalance of 15 He Erji is related to menopause. The possibilities represent individual embodiments of the invention. For example, the findings shown in Figures 1 to 5 confirm that the selective androgen receptor modulator (SARM) prevents the reduction of bone mineral bifurcation throughout the body and at several specific sites. The studies used an osteoporosis 20 model of osteoporosis (0νχ) rats that has been shown to highly predict the success of osteoporosis therapy in humans (Kalu DN in Bone Miner Issue 15 pp. 175-91 (1991) B). Decreased bone mineral density is a key marker of osteoporosis' and is associated with decreased bone strength and increased fracture rate. By preventing the decrease in bone mineral density, these symptoms of osteoporosis can also be prevented at the same time. 19 200526202 and other symptoms. The findings shown in Figures 12 to 13 show that selective androgen receptor regulator (SARM) increases bone mineral content, which is another marker of bone strength in osteoporotic mice, further confirming The findings shown in the figure. 5 In another embodiment, the present invention provides a method for increasing bone strength in a body, comprising administering to the individual a selective male stress, receptor receptor (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate or oxooxide of a SAR compound Any repair 10 composition. In another embodiment, the invention provides a method for increasing the bone quality of a body, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, 15 pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or N-oxide or any of the SARM compounds. A composition. Methods for assessing bone quality, bone strength and bone quality are well known in the art. For example, in one embodiment, a biomechanical test is used to assess bone strength. In one embodiment, DEXA (Figures 2, 4, M, 15, 20, 20, 17 to 19, 25, and 26) or pQCT (Figures 6 to 9 and 20 to 23) are used to evaluate; bone quality . Bone quality can be assessed by measuring bone mineral content (Figures 12 to 13). Other methods for assessing m-bone strength are described, for example, in the text of Faulkner et al. (Am J Roentgen 010gy 157, pp. 1229_1237 (1991)). Each method represents an individual embodiment of the invention. 20 200526202 Similar results were obtained with the multiple methods of the present invention for measuring bone mass, strength and quality. The consistency of the results obtained by the different methods once again confirms the experimental results of the present invention. In another embodiment, the present invention provides a method for increasing bone mass 5 of a body, comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate or sense oxide of a SARM compound, or any combination thereof Thing. 10 In another embodiment, the present invention provides a method for reducing the incidence of osteolytic effects in a body, which comprises administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method includes administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or 15 N-gas of a SARM compound or Any ^ group of compounds. In another embodiment, the present invention provides a method for preventing osteolytic effects in a body, which comprises administering one of the aforementioned compounds. In another known example, the present invention provides a method for suppressing the osteolytic | worming effect in a body &apos;, which includes the same administration effect. In another embodiment 20, the present invention provides a method for inhibiting osteolytic effect in a body ', which comprises the same administration effect. In one embodiment, the main mechanism for the reduction of bone mass and / or bone strength due to osteoporosis, menopause, and androgen deficiency is osteolysis. The method for measuring the effect of osteolytic silver is well known in the art. Example 21 200526202 Such as 'in one embodiment, Keyi 丄 ,,' ”wrong analysis of serum osteocalcin levels, and to measure the role of bone silk, serum bone! Bowelin system is related to the level of osteocalcin K even. In another embodiment, bone miscellaneous work can be evaluated by measuring the density of the bone disc material (Figures 12 to 13). In another case, the osteolytic effect can be measured by analyzing the level of deoxygenated mouth in the urine compared to that of ketidine. In another known example, the role of bone growth can be estimated by analyzing the level of insulin-type growth factor (1) in the blood '. The various methods used to assess the effects of osteolytic surrogates represent individual embodiments of the invention. In the other-real _ + '"f-dissolving materials, refers to the loss of moon shell &quot; IL due to osteoclasting effect. The human bone network from time to time undergoes a dynamic renewal process, which includes the monthly / combined effect and bone Formation effect. In this example, the osteolytic action is based on the osteoclast destruction of the bone matrix. Most of the osteocolonic disorders result from the balance between osteogenesis and osteolysis. During the ongoing remodeling process, osteoporosis occurs if the new bone formation effect is relatively less than the effect of osteolytic surname 15. In one embodiment, the individual treated by the present invention has osteoporosis. In another-implementation In one embodiment, the individual has osteoporosis. In another embodiment, the individual has an increase in osteolytic effect. In another embodiment, the individual has a fracture. In another embodiment, the individual Suffer from bone fragility. 20 In another embodiment, the individual has a reduced bone mineral density. In another embodiment, the individual has osteoporosis, osteopenia, increased osteolytic effects, fractures, Weak bones and / or dense bone minerals Any combination of reduced degrees. Each condition represents an individual embodiment of the present invention. For example, the findings shown in Figures 1 to 13 show that treatment with selective male 22 200526202 sex hormone receptor modulator (SARM) can Depending on the region and type of bone being evaluated, partial or complete prevention of osteolytic effects, decreased bone mineral density, and reduced bone strength due to ovarian removal. Therefore, selective androgen receptors (SARM) is suitable for reducing the incidence of osteolytic effects, reduced bone mineral density, and reduced bone strength in a body, such as due to 5 being osteoporosis, menopause, or any of the diseases or conditions described in the present invention In one embodiment, the individual treated by the present invention is a male individual. In another embodiment, the individual is an aging male individual. In another embodiment 10, the individual is a castrated male Individual. In another embodiment, the individual is a male undergoing androgen deficiency treatment. In another embodiment, 'the individual has prostate cancer. In another embodiment, the individual (male (Sexual or female) has another type of cancer. In another embodiment, the individual is undergoing chemotherapy. In another embodiment, the individual has recently undergone chemotherapy. 15 In another embodiment, the individual Is a female individual. In another embodiment, the individual is an aging female individual. In another embodiment, the individual is an HIV-positive premenopausal female individual. In another implementation, the individual is A female individual suffering from Addison's disease. In another embodiment, the individual is a female individual suffering from a pituitary dysfunction. In another embodiment, the individual is a female Ovariectomized female individual. In one embodiment, the individual to which the SARM compound of the present invention is administered is an aging individual. In one embodiment, the term "aging" refers to a process of aging. In another embodiment, the aging system refers to a body over the age of 200526202. In another embodiment, the aging system refers to a body over 45 years old. In another embodiment, the aging system refers to an individual over 50 years of age. In another embodiment, the aging individual refers to an individual over 55 years of age. In another embodiment, the aging system refers to a body over 60 years of age. In another embodiment, the aging system refers to a body older than 65 years. In another embodiment, the aging system refers to an individual over 70 years old. In another embodiment, the .aging system refers to one individual. Each type of system represents an individual embodiment of the invention. Lu In another embodiment, the subject treated by the present invention does not suffer from osteoporosis, osteoporosis, increased osteolytic effects, fractures, weak bones, and / or decreased bone mineral density. The findings shown in Figures 16 to 24 show that the 'selective androgen receptor regulator (SARM) can reverse the pre-existing reduction in bone mineral density and bone strength caused by osteoporosis. Therefore, the selective androgen receptor modulator (SARM) has an anabolic activity, which is independent of its activity to prevent osteolysis. Therefore, the positive effects of selective androgen receptor modulators (SARMs) on bone mineral density, bone strength, and monthly quality are by no means limited to individuals who have experienced or are experiencing bone-related disorders; conversely, selective androgen receptors The benefits of regulators (SARMs) can be applied to any situation where an increase in bone mineral density, bone strength, or bone quality is desired. 10 15 20 Therefore, in another embodiment, the present invention provides a method for reversing a decrease in bone mineral density in a body, which comprises administering a selective androgen receptor regulator (SARM) or its metabolism Thing or derivative. In another 24 200526202-embodiment, the present invention provides a method for reversing osteoporosis in an individual, comprising administering a selective androgen receptor modulator (SARM) or a metabolite thereof or derivative. In another embodiment, the present invention provides a method for reversing osteopenia in an individual, which comprises administering to a selective male hormone receptor modulator (SARM) or its metabolite = derivative. In another embodiment, the present invention provides a method for reversing bone fragility in a body, which comprises administering a selective androgen · fork regulator (SARM) or a metabolite or derivative thereof. In one embodiment, reduced bone mineral density, osteoporosis, osteoporosis, or osteoporosis # 10 may be due to menopause or another hormonal disorder or imbalance. Each method represents an individual embodiment of the invention. There are several different types of bone in the bone network, such as cortical bone and trabecular bone. The cortical bone system acts as a protective covering and surrounds the bone trabeculae. Cortical bone has three layers: the periosteal sheath (the outer surface of the bone); the inner cortical sheath (the middle 15 layers); and the endoperiosteal sheath (the layer adjacent to the bone marrow cavity). Cortical bone accounts for the majority of hands and feet and is responsible for bone strength. In one example, the cortical bone may also be referred to as Haversian bone or compact bone. In one example, the trabecular bone, which plays a role in the metabolism of bone, is also known as spongy bone or cancellous bone. The ratio of cortical bone to trabecular bone varies with bones throughout the body. v 20 Thus, in one example, the bone with increased strength and mass is cortical bone. The beneficial effects of selective androgen receptor regulators (SARMs) on cortical bone are shown in Figures 6 to 8 and Figures 20 to 22. In another example, the bone is a trabecular bone. The beneficial effects of selective androgen receptor regulators (SARMs) on trabeculae are shown in Figures 9 and 23. In another example, the bone 25 200526202 is Song Beiyue. In another example, the bone is a Haversian bone. In another example, the bone is a complete bone containing multiple types of bone tissue. In another example, a particular layer of cortical bone may be affected by the method of the invention. In one example, the layer is periosteum. In one example, 5 the layer is a cortical inner sheath. In one example, the layer is an endoperiosteal sheath. Each type of bone represents an individual embodiment of the invention. In another embodiment, the present invention provides a method for reducing fat mass (FM) of a body, which comprises administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method 10 comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, agent, hydrate, or N_oxide of a SARM compound Any composition. In another embodiment, the present invention provides a method for reducing the incidence of increased fat mass (FM) in a body, comprising administering to the individual 15 a selective androgen receptor modulator (SARM) Compounds. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound combination. In another embodiment, the present invention provides a method for increasing the muscles of a body 20 transient + berry, which comprises administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of a SARM compound combination. 26 200526202 In another embodiment, the present invention provides a method for reducing the incidence of decreased muscle mass in an individual, comprising administering to the individual a selective androgen receptor modulator (SARm) compound. In another embodiment, the 4 method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, medicament, hydrate, or N-oxide of the SARM compound A composition. In another embodiment, the present invention provides a method for increasing the diaphragmatic berry of a body comprising administering to the individual a selective androgen receptor modulator (SARM) compound. In another embodiment, the method includes administering an analog, derivative, isomer, metabolite of a SARM compound to an acceptable salt, agent, hydrate, or N-oxide or Any composition. The findings in the seventh case showed that the selective androgen receptor regulator 15 20 (ARM) reduced the percentage of fat mass and increased the diaphragm muscle mass in human ovarian-excluded animals. Lean muscle mass affects fractures due to several factors. The increase of the 100th A _ f amount indirectly causes the increase of bone minerals. The increase in the degree of negative muscles may increase balance and muscle strength, and the risk of falling is the risk of a fall in the elderly. The 'box' for reducing the risk of fractures. The present invention provides a reduced risk of material loss by increasing muscle mass. This day's dip peak has a low secret quality, and now shows that selectivity is a method. Furthermore, the fat mass and the hormone receptor regulator (SARM) shown in Fig. 26 can reverse the current research, and the phenomenon of 3σ can be reversed. Coupled with the weight study shown in Figure 25, a special study found that there was a decrease in the quality of diaphragm muscles that had been reversed. 27 200526202 疋 讦, 雒 雒 夸 muscle mass and 痩 muscle mass 2 W regulator (SARM) for individuals with fat mass, related to the disease, and vice versa: the surface effect is by no means limited to undergoing bone mass plus lean muscle mass Saki I, as a matter of wealth, reduced the amount of ship f and increased the number of shells. In one embodiment, "the total amount of π. Fat mass in another implementation refers to the percentage of fat in the body. In another-it depends on h #, refers to the body fat, shellfish. In her example, "fat mass" refers to the total monthly and daily fats in a particular middle region of the body, or the percentage of body fats. In another embodiment, "month t 10

"Fat mass" refers to the amount or percentage of a specific type of fat. The purpose of each type: Quality represents the present embodiment.-In the examples, the fat affected by the present invention is subcutaneous fat. The fat is lying body fat. In another embodiment, the month fat is intra-abdominal. In another embodiment, the fat is another type of month fat known in the art. 15 Types of fat represent individual embodiments of the invention.

In the actualized example, 'reduction of fat mass and increase of diaphragm muscle mass and / or muscle placement' have a positive effect on impaired glucose metabolism. In another embodiment, a decrease in fat mass and an increase in diaphragm muscle mass and / or muscle berry 'has a positive effect on diabetes. In another example 20 cases, the decrease in fat mass and the increase in lean muscle mass and / or muscle mass have a positive effect on facial A pressure. In another embodiment, the decrease in fat mass and the increase in diaphragm and / or muscle mass have a positive effect on coronary heart disease. In another embodiment, a decrease in fat mass and an increase in diaphragm muscle mass and / or muscle mass have a positive effect on obesity. In 28 200526202, in another embodiment, a decrease in fat mass and an increase in lean muscle mass and / or muscle mass are associated with a disease or disorder associated with impaired glucose metabolism, diabetes, hypertension, coronary heart disease, or obesity. The illness has a positive effect. Thus, in another embodiment, the present invention provides a means for treating or improving impaired glucose metabolism, diabetes, hypertension, coronary heart disease, obesity, or a related disease or disorder, comprising administering Selective androgen receptor regulator (SARM) or a derivative or metabolite thereof. Selective androgen receptor modulation early: In one embodiment, the selective androgen receptor modulator 10 (SARM) compound of the present invention is a novel type of androgen receptor (ar) -directed agent that is shown to produce Androgenic or anti-androgenic and anabolic activity. In another embodiment, the selective androgen receptor modulator (SARM) compounds of the present invention are a novel type of non-steroidal ligands for androgen receptors. 15 In another embodiment, the selective androgen receptor modulator (SARM) compounds of the present invention can be divided into several subtypes based on their biological activity. For example, several SARM compounds have synergistic effects on muscle or bone, while others have antagonist effects. 20 Androgen receptor (AR) is a ligand-activated transcriptional regulator protein that regulates the induction of male sexual development and function through its activity and endogenous androgens (male hormones). Androgen hormones (such as 1-hydrotestosterone (DHT) and testosterone) are steroids made from testes and adrenal cortex in the body. Therefore, in one embodiment, as an androgen receptor,

The difference between SARM and previously known androgen receptor 29 200526202 SARM is a non-steroid. In one embodiment, the receptor synergist is a substance that binds to the receptor and activates them. In one embodiment, the receptor portion synergist is a substance that binds to the receptor and activates such portions. In one embodiment, the receptor 5 antagonist is a substance that binds to and deactivates the receptor. In one embodiment, the SARM compound of the present invention has a tissue-selective effect, wherein depending on the tissue, an agent may be a synergist, a partial synergist, and / or an antagonist. For example, a 'SARM compound can stimulate muscle tissue and simultaneously inhibit prostatic tissue. In one embodiment, the SARM of the present invention is an androgen receptor 10 (AR) synergist. In another embodiment, the SARM of the invention is an androgen receptor antagonist. Analytical methods for determining whether a compound of the present invention is an AR synergist or antagonist are well known to those skilled in the art. For example, the SARM compound can be used to monitor and / or stimulate the growth of tissues containing androgen receptors, such as the prostate and seminal vesicles, such as by measuring the activity of the androgen receptor equivalents. The androgen receptor antagonist activity can be measured by monitoring the SARM compound to inhibit the growth of tissues containing the androgen receptor. In another embodiment, the slave compounds of the present invention can be classified as partial androgen receptor synergists / antagonists. These readings are synonymous with androgen receptors in some groups, resulting in increased transcription of male hormone receptor-responsive genes (such as muscle and anabolic effects). In other organizations, these compounds act as competitive inhibitors of Pycnogenol and Diazepinone (DHT) on androgen receptors to prevent the inherent androgenic effect of androgens. Each type of selective androgen receptor regulator (sarm) 30 200526202 represents individual embodiments of the invention. In one embodiment, a SARM compound of the invention is reversibly bound to an androgen receptor. In another embodiment, the SARM compound is irreversibly bound to the androgen receptor. In one embodiment, the compound of the present invention may contain a functional group (affinity label) to allow alkylation (ie, covalent bond formation) of the androgen receptor. Therefore, in this case, the compound binds to the receptor in an irreversible manner, and thus cannot be replaced by a steroid such as the endogenous ligands DHT and testosterone. In one embodiment of the invention, a selective male 10 hormone receptor modulator (SARM) compound is administered to the individual. In another embodiment, an analog of SARM is administered. In another embodiment, a derivative of SARM is administered. In another embodiment, an isomer of SARM is administered. In another embodiment, a metabolite of SARM is administered. In another embodiment, a pharmaceutically acceptable salt of sarm is administered. In another embodiment, a medicament of SARM 15 is administered. In another embodiment, the monohydrate of SARM is administered. In another embodiment, an N-oxide of SARM is administered. In another embodiment, the method of the present invention comprises administering any combination of an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical agent, hydrate, or quinoxide of SARM Thing. Each possibility represents an individual embodiment of the invention. 20 In one embodiment, the term "" isomer "refers to an optical isomer. In another embodiment, "isomer" refers to an analog. In another embodiment, "isomer" refers to a structural isomer. In another embodiment, "isomer" refers to a structural analog. In another embodiment, the isomer is a configurational isomer. In another embodiment, "isomer" refers to a configurational analog. 200526202 In another embodiment, "isomer" refers to any other isomer known in the art. Each type of isomer represents a separate embodiment of the invention. In alternative embodiments, the invention encompasses the use of different optical isomers of the read compounds. Skilled artisans will understand that the present invention should contain at least 5 chiral centers. Thus, reads used in the method of the invention may exist and be separated in optically active or racemic forms. -Some compounds may also exist in polymorphic forms. It should be understood that the present invention encompasses any foreign material, optically active, polymorphic or stereoisomeric forms, or mixtures thereof, all of which are! The raw shellfish is suitable for treating androgen-related conditions described herein. 10 In one embodiment, SARM is a pure W-isomer. In another embodiment ARM is a hydrazone-isomer. In another embodiment, it is a mixture of (R) and ⑻. Isomers. In another embodiment, the proof of M includes a racemic mixture of (R) and one of the hydrazone-isomers in equal amounts. It is well known in the art how to prepare optically active forms (e.g., by isolation of 15 racemic forms other than recrystallization techniques, synthesis by optically active starting materials, by chiral synthesis, or by (A chiral stationary phase was used to analyze the separation). In another embodiment, the present invention includes amine-substituted compounds and pharmaceutically acceptable compounds of organic and inorganic acids such as citric acid and chloric acid. The present invention also includes ① oxides of the compound lysedyl. · J is processed by, for example, sodium hydroxide treatment, and can also be prepared from age-old compounds to treat the salt. At the same time, it is possible to prepare this compound with aliphatic and aromatic carboxylic acids such as acetic acid and benzyl. In another example, the present invention further includes 32 200526202 derivatives of SARM compounds. "Derivatives, -Yanji includes, but is not limited to, riding creatures, acid derivatives, amidine derivatives, and other bio-organisms. In addition, the present invention further includes hydrates of sarm compounds." Hydrate "-words including but not Limited to hemihydrate, monohydrate, dihydrate, trihydrate, etc. 5 In another embodiment, the present invention further includes metabolites of SARM compounds. In one embodiment, "metabolites,- A word is any substance that is produced from another substance by metabolic action or method. In a practical example, the present invention further includes a drug of a SARM compound. In one embodiment, the term "medicine" refers to a composition (pharmaceutical composition) suitable for use in one of the 10 pharmaceutical uses defined herein. In one embodiment, the "selective androgen receptor of the invention is regulated (SARM) compound, which is one of the compounds represented by the structure of the chemical formula:

In another embodiment, the SARM compound of the present invention is one of the compounds represented by the structure of formula II in the chemical formula ...

II where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 33 200526202 Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, basic, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 5 NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a condensed ring system represented by structural formula A, B or C;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, 10 CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH. In another embodiment, the SARM compound is a compound of formula π, where X is oxygen. In another embodiment, the SARM compound is a compound of Formula II, wherein Z is NO. In another embodiment, the SARM 15 compound is a compound of Formula II, wherein Z is CN. In another embodiment, the SARM compound is a compound of formula VII, wherein Y is CF3. In another embodiment, the SARM compound is a compound of formula II, wherein Q is NHC0CH3. In another embodiment, the SARM compound is a compound of formula II, wherein Q is fluorine. 20 In one embodiment, the substituent R in the compound XI or (II) is an alkyl group. In another embodiment, the substituent &amp; is an A-substituted alkyl group. In another embodiment, the substituent R is a dihaloalkyl. In another embodiment, the substituent R is a trihalo 200526202 alkyl group. In another embodiment, the substituent R is a Cj ^ F moiety. In another embodiment, the substituent R is a CHF2 moiety. In another embodiment, the substituent R is a CF3 moiety. In another embodiment, the substituted scale is a CRCF3 portion. In another embodiment, the substituent r is aryl. In another embodiment, the substituent R is phenyl. In another embodiment, the substituent R is fluorine. In another embodiment, the substituent R is iodine. In another embodiment, the substituent R is bromine. In another embodiment, the substituent is chlorine. In another embodiment, the substituent R is a fluorenyl. In another embodiment, the substituent R is an OH moiety. Each substituent represents a separate embodiment of the invention. Book 0 In another embodiment, the SARM compound of the present invention is a compound represented by the structure of Formula III:

III where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; 15 R1 is CH3, CH2F, CHF2, cf3, CH2CH3 or CF2CF3; τ is OH, or,- NHC0CH3 or NHCOR; R is alkynyl, haloalkyl, dihaloalkyl, trihaloalkyl, Ch2f, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, fluorene, molybdenum, chlorine, fluorenyl, or 0H; 20 A is Selected from the group consisting of: 35 200526202

Where A and B cannot be a benzene ring at the same time; 5 Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3;

(^ And () 2 are each independently hydrogen, alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, 10 NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO,

Q3 and Q4 are each independently hydrogen, alkyl, fluorine, iodine, bromine, gas, cf3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, 15 NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR , NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN or NCO; 36 200526202 W] is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. In one embodiment, the SARM compound is a compound of formula III, wherein X is oxygen. In another embodiment, the SARM compound is a compound of formula III, wherein G is oxygen. In another embodiment, the SARM compound is a compound of formula III, wherein T is OH. In another embodiment, the SARM compound is a compound of formula III, wherein 仏 is CH3. In another embodiment, the SARM compound is a compound of formula III, wherein Z is NO2. In another embodiment, the SARM compound is a compound of Formula III, wherein Z is CN. In another embodiment, the SARM compound is a compound of Formula III, wherein γ is CF3. In another embodiment, the SARM compound is a compound of formula in which is NHCOCH3. In another embodiment, the SARM compound is a compound of formula III, wherein Q is fluorine. 15 In one embodiment, the substituents Z and Y may be located at any position in the% (hereinafter referred to as A). In one embodiment, the substituent Z is in the para position of the A ring. In another embodiment, the substituent γ is located at the meta position of the A ring. In another embodiment, the substituent 2 is located in the para position of the A ring, and the substituent Y is located in the meta position of the A ring. 20 In one embodiment, the substituents Qi and Q2 may be located at any position in a ring having these substituents (hereinafter referred to as “B ring,”). In one embodiment, the base 仏 is located at B Para position of the ring. In another embodiment, the substituent α is hydrogen. In another embodiment, the substituent 仏 is located at the para position of the B ring, and the substituent Q2 is hydrogen. In another embodiment, The substituent Q2 is hydrogen. In another example 37 200526202, the 'substituent (^ 1 is) ^ 11 (^ 0 (1! 113 and the para position of the B ring, and the substituent q2 is hydrogen. Each of the above variables Each substituent in the present invention represents an individual embodiment of the present invention. Furthermore, each position listed in each of the above substituents represents an individual embodiment of the present invention. In another embodiment, the present invention The SARM compound is one of the compounds represented by the structure of Chemical Formula IV:

Wherein X is a bond, oxygen, CH2, NH, Shixi, PR, NO or NR; 10 G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is an alkyl group, a halogenated alkyl group, Dihalo, trihalo, CHF2, CF3, CF2CF3, aryl, phenyl, I, iodine, molybdenum, fluorenyl, or OH; 15 R1 is CH3, CH2F, chf2, CF3, CH2CH3 Or cf2cf3; R2 is fluorine, gas, bromine, fluorene, CH3, CF3, 0H, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is gas, chlorine, bromine, basic, CN, N02, COR, COOH, CONHR, 20 CF3, S11R3; or &amp; together with the benzene ring connected to it, it is formed by the following structural formula Representative fused ring system; 38 200526202

Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3 , 5 NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OSO2R, S02R, SR; or the benzene ring to which Q is connected Together they are a fused ring system represented by structural formula A, B or C;

η is an integer from 1 to 4; and m is an integer from 1 to 3. In one embodiment, the SARM compound is a compound of formula IV, wherein X is oxygen. In another embodiment, the SARM compound is a compound of formula 15 wherein G is oxygen. In another embodiment, the SARM compound is a compound of formula IV, wherein z is no 02. In another embodiment, the SARM compound is a compound of formula Iv, wherein z is CN. In another embodiment, the SARM compound is a compound of formula IV, wherein Y is CF3. In another embodiment, the SARM compound is a compound of Formula IV, wherein Q is NHC0CH3. In another embodiment 200526202, the SARM compound is a compound of formula IV, wherein Q is fluorine. In another embodiment, the SARM compound is a compound of formula IV, where T is OH. In another embodiment, the SARM compound is a compound of formula IV, wherein Ri is CH3. In another embodiment, the 'SARM 5 compound is a compound of formula IV, wherein Q is fluorine and R 2 is CH 3. In another embodiment, the &apos; SARM compound is a compound of formula IV, wherein Q is fluorine and R2 is gas. In one embodiment, the substituents Z, Y, and R3 may be located at any position in a ring having these substituents (hereinafter referred to as "A ring"). In one embodiment, the Z-based radical Z is located at the para position of the A ring. In another embodiment, the substituent γ is at the meta position of the A ring. In another embodiment, the substituent z is in the para position of the A ring, and the substituent Y is in the meta position of the A ring.

In one embodiment, the substituents Q and R2 may be located at any position in a ring having these substituents (hereinafter referred to as "B ring"). In one embodiment, the substituent 15 Q is located in the para position of the B ring. In another embodiment, the substituent Q is in the para position of the B ring. In another embodiment, the substituent 卩 is 1 ^ 11 (:: 〇 (:: 113 and is located in the para position of the B ring. In one embodiment, when the integers m and η are greater than 1, the substituents are represented by 2 and The intention is not limited to-specific substituents, and may be any combination of the above-listed substituents. Each substituent in each of the above-mentioned variants represents an individual embodiment of the present invention, and furthermore, among the above-mentioned substituents Each of the positions listed represents an individual embodiment of the present invention. Moreover, each of the values listed in the above integers represents an individual embodiment of the present invention. 40 200526202 In another embodiment, the SARM of the present invention The compound is one of the compounds represented by the structure of Chemical Formula V:

V of which 5 R2 is rat, chlorine, hydrogen, ethene, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, aryl, OR, NH2, NHR, NR2, SR; R3 It is fluorine, gas, moth, CN, No2, COR, COOH, CONHR, CIF3 S11R3 'or R3 together with the benzene ring connected to form a fused ring system represented by the following structure 10;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, fluorine, gas, bromine, iodine, alkenyl, or OH; 15 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, chlorine, bromine, iodine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 41 200526202 NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OS02R, S02R, SR; or Q and the benzene ring to which it is connected together are a Fused ring system represented by structural formula A, B or C;

c 5 η is an integer from 1 to 4; and m is an integer from 1 to 3. In another embodiment, SARM is a compound of formula V, wherein Z is N02. In another embodiment, SARM is a compound of formula V 'wherein Z is CN. In another embodiment, SARM is a compound of formula V10, wherein Y is CF3. In another embodiment, SARM is a compound of formula V, wherein q is NHC0CH3. In another embodiment, SARM is a compound of formula v, where q is fluorine. In another embodiment, SARM is a compound of formula V, wherein Q is fluorine and R2 is CH3. In another embodiment, SARM is a compound of formula V, where Q is fluorine and r2 is gas. As discussed in the above compound IV, in one embodiment, the substituents z, Y and R3 may be located at any position in the A ring; and in an embodiment, q and may be located at any position in the B ring. Furthermore, as described above, when the integers 111 and 11 are greater than 1, the substituents R2 and &amp; are not limited to a specific substituent, and may be any combination of the substituents listed in 20 above. Each substituent in each of the above variants represents an individual embodiment of the invention. In addition, the positions listed in the above substituents represent individual examples of the present invention. In addition, the numerical values listed in the above integers represent individual embodiments of the present invention. In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Formula VI.

As explained above, the findings of the present invention show that compound VI has a beneficial effect on bone, fat and muscle tissue. In addition, the pharmacokinetic properties of the compound VI facilitate its use as a pharmaceutical therapy as one of the conditions disclosed in the present invention. The present invention has shown that compound VI 10 exhibits lower metabolic clearance and better oral bioavailability compared to testosterone. At doses that inspire optimal pharmacological effects (case 15), these properties of the compound VI were observed and peak plasma concentrations were reached rapidly. In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Formula VII.

In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Formula VIII. 43 200526202

nhcoch3 In another embodiment, the SARM compound of the present invention is a compound represented by the structure of Formula IX.

5 In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Chemical Formula X.

In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Formula XI.

In another embodiment, the SARM compound of the present invention is a compound represented by a structure having Formula XII. 44 200526202

In one embodiment, ''. In another embodiment, in one embodiment, p is 4. In one embodiment, H is p. The radical is bounded by the aforementioned chemical formula IV, and P is 3. In another embodiment, in another embodiment, the SARM compound of the present invention represented by the structure of the formula XIII is a chemical compound. o2n

hC

XIII In another embodiment, the SARM compound of the present invention represented by the structure of formula XIV is a chemical compound. 10

XIV In another embodiment, the structure of the formula XV represents _

The SARM compound of the present invention is a chemical compound.

In another embodiment XV-in the embodiment, p is P41. In the embodiment, P is 2m. As in the above chemical embodiment, P 'is 4. Defined by the rest of the; 45 15 200526202 In another embodiment, the S ARM compound of the present invention is a compound represented by the structure of Formula XVI.

In another embodiment, the SARM compound of the present invention is one of the compounds represented by the structure of Formula XVI.

In one embodiment, SARM is a compound of formula XVII, wherein Q is acetamido (NHCOCH3). In another embodiment, SARM is a compound of formula XVII, wherein Q is trifluoroacetamido 10 (NHCOCF3). In another embodiment, SARM is a compound of formula XVII, where Z is N02 . In another embodiment, SARM is a compound of formula XVII, wherein Z is CN. In another embodiment, SARM is a compound of formula XVII, wherein Z is COR. In another embodiment, 15 SARM is a compound of formula XVII, wherein In another embodiment, SARM is a compound of formula XVII, wherein γ is CF3. In another embodiment, SARM is a compound of formula XVI1 46 200526202, wherein Y is iodine. In another embodiment, SARM is a compound of formula XVII, wherein γ is bromine. In another embodiment, Sarm is a compound of formula XVII, wherein γ is chlorine. In another embodiment, SARM is a compound having the chemical formula χνπ, wherein Y is SnR3. 5 In another embodiment, SARM is a compound of formula XVII, wherein R is an alkyl group. In another embodiment, SARM is a compound of formula XVII, wherein R is 0H. Each substituent in each of the above variants represents an individual embodiment of the invention. In addition, the positions listed in each of the above substituents represent individual examples of the present invention. In another embodiment, the SARM compound of the present invention is one of the compounds represented by the structure of Formula XVIII: 7

15 T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, C00H, COR, NHC0R or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, fluorine , Iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHC0CH3, NHC0CF3, NHCOR, NHCONHR, 20 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR; or Q together with the benzene ring to which it is connected is a fused ring system represented by structural formula A, 47 200526202 B or C;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl 5 or OH; and R ^ CH3, CH2F , CHF2, CF3, CH2CH3, or CF2CF3. Each substituent in each of the above variants represents an individual embodiment of the invention. In addition, the positions listed in each of the above substituents represent individual examples of the present invention. 10 In one embodiment, the SARM compound is a compound having one of the above formulae, wherein X is oxygen. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein X is a bond. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein X is CH2. In another embodiment, the SARM 15 compound is a compound having one of the above formulae, wherein X is NH. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein X is selenium. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein X is PR. In another embodiment, the SARM compound is a compound having one of 20 in the above chemical formula, wherein X is NO. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein X is NR. In one embodiment, the SARM compound is a compound having one of 48 200526202 in the above chemical formula, wherein G is oxygen. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein G is sulfur. In one embodiment, the SARM compound is a compound having one of the above formulae, wherein T is OH. In another embodiment, the SARM 5 compound is a compound having one of the above formulae, wherein T is OR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein T is -NHC0CH3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein T is NHCOR. 10 In one embodiment, the SARM compound is a compound having one of the above formulae, wherein B is 1 ^ 02. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Z is CN. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Z is C00H. In another embodiment, the 15 SARM compound is a compound having one of the above formulae, wherein Z is COR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Z is NHCOR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Z is CONHR. 20 In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Y is CF3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Y is fluorine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Y is Angstrom. In another embodiment, the SARM 4949 26202 compound is one of the above chemical formulae, wherein γ is bromine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein hydrazone is chlorine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Υ is CN. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Y is CR3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Y is SnR3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHCOCH3. In another embodiment, the 10 SARM compound is a compound having one of the above formulae, wherein Q is fluorine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is an alkyl group. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is iodine. In another embodiment, the SARM compound is a compound having one of the above Chemical Formula 15, wherein Q is bromine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is gas. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is CF3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is 20 CN. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is CR3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is SnCR3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NR2. In another embodiment, the 50 200526202 SARM compound is a compound having one of the above formulae, wherein Q is NHCOCF3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHCOR. In another embodiment, the SARM compound is a compound 5 having one of the above formulae, wherein Q is NHCONHR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHCOOR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is 0C0NHR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is CONHR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHCSCH3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is nhcscf3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHCSR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHS02CH3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NHS02R. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is 20 OR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is COR. In another embodiment, the SARM compound is a compound having one of the above chemical formulas, wherein Q is 0COR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is OS02R. In another embodiment, the 200526202 SARM compound is a compound having one of the above formulae, wherein Q is S02R. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is SR. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein 5 Q is SCN. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NCS. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is OCN. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q is NCO. 10 In another embodiment, the SARM compound is a compound having one of the above formulae, wherein Q together with the benzene ring to which it is attached is a fused ring system represented by structural formula A, B or C;

In another embodiment, the SARM compound is a compound having one of 15 in the above formula, wherein R is an alkyl group. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is a halogenated alkyl group. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is a di-i-alkyl group. In another embodiment, the SARM compound is a compound having one of the above formulae, 20 wherein R is a tri-i-alkyl group. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is CH2F. In another embodiment, the SARM compound is one of the compounds of the above formula 52 200526202, wherein R is CHF2. In another embodiment, the 'SARM compound is a compound having one of the above formulae, wherein R is CF3. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is CF2CF3. In another embodiment, SARM compound 5 is a compound having one of the above formulae, wherein R is an aryl group. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is phenyl. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is fluorine. In another embodiment, the SARM compound is a compound having one of the above formulas, wherein R is iodine. In another embodiment, the 'SARM compound is a compound having one of the above formulae, wherein R is bromine. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein R is chlorine. In another embodiment, the SARMt compound is a compound having one of the above formulae, wherein R is a dilute group. In another embodiment 15, the SARM compound is a compound having one of the above formulae, wherein R is OH. In another embodiment, the SARM compound is a compound having one of the above formulae, wherein 1 is a 0: ratio. In another embodiment, the SARM compound is a compound having one of the above chemical formula 'wherein R1 is 20 CH2F. In another embodiment, the SARM compound is a compound having one of the above chemical formula 'wherein Ri is CHF2. In another embodiment, the 'SARM compound is a compound having one of the above formulae, wherein R ^ CF3. In another embodiment, the SARM compound is a compound having one of the above formulas' wherein Ri is CHfH3. In another embodiment 53, 200526202, the SARM compound is a compound having one of the above chemical formulas, where 1 is 0-20? 3. Each of the substituents of 乂, 、, 2, 0, D, 卩, 11 and 111 in each of the above chemical formulas represents individual embodiments of the present invention. In addition, the positions listed in each of the above-mentioned radicals are representative of individual embodiments of the present invention. Moreover, the numerical values listed in the above integers represent individual embodiments of the present invention.

In another embodiment, the SARM compound of the present invention is a compound represented by the structure of Formula XIX:

In another embodiment, the SARM compound of the present invention is one of the compounds represented by the structure of Formula XX:

In another embodiment, the SARM compound of the present invention is a compound represented by the structure having the formula XXI:

In another embodiment, the SARM compound of the present invention is a compound represented by a structure having the formula 54 XXII 202 XXII:

XXII. In another embodiment, the SARM compound of the present invention is one of the compounds represented by the structure of Formula XXIII:

XXIIJ. In another embodiment, the SARM compound of the present invention is a compound represented by a structure having the formula XXIV:

In one embodiment, "alkyl" refers to a saturated aliphatic hydrocarbon, including linear, branched, and cyclic alkyl groups. In one embodiment, the alkyl group has 1 to 12 carbons. In another embodiment, the alkyl group has 1 to 7 carbons. In another embodiment, the alkyl group has 1 to 6 carbons. In another embodiment, the alkyl group has 1 to 4 carbons. The alkyl group may be unsubstituted or substituted with one or more groups selected from the group consisting of fluorine, iodine, bromine, gas, hydroxyl, alkoxycarbonyl, amine, amine, and amine. Based on amino, succinyl, amine, alkynyl, dialkyl, weiyl, thio, and thioalkyl. In one embodiment, "alkenyl" refers to an unsaturated hydrocarbon, which includes a straight chain, a branched chain, and a cyclic group having one or more double bonds. An alkenyl group may have one double bond, two double bonds, three double bonds, and the like. Examples of alkenyl are ethylene, allyl, butenyl, cyclohexenyl and the like. The alkenyl group may be unsubstituted or substituted with one or more groups selected from the group consisting of fluorine, ethene, bromine, gas, mesityl, alkoxycarbonyl, amido, alkyl, amido, di Alkylamino, nitro, amino, alkylamino, dialkylamino, carboxyl, thio, and thioalkyl. In one embodiment, "haloalkyl" refers to an alkyl group as defined above, which is substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or hard substitution. In one embodiment, "aryl" refers to an aromatic group having at least one carbocyclic aromatic group 10 or a heterocyclic aromatic group; it may be unsubstituted or substituted by one or more groups selected from the group consisting of Substitution: Fluorine, Ion, Bromine, Gas, Benzyl, Alkyl, Dioxo, Alkyl, Alkyl, Dialkyl, Nitro, Amine, Alkyl Group, amidoamino, carboxyl or thio or thioalkenyl. Non-limiting examples of aryl rings are phenyl, naphthyl, pyranyl, 15 pyrrolyl, pyrimidinyl, pyrimidinyl, pyrazolyl, pyridyl, furyl, phenylthio, thiazolyl, imidazolyl, Isoxazolyl and the like. In one embodiment, "hydroxy" refers to an OH group. "Alkenyl" refers to a group having at least one carbon-carbon double bond. In one embodiment, the dentino refers to gas, gas, &gt; odor or moth. In one embodiment, "fragrant An alkyl group refers to an alkyl group bonded to an aryl group, wherein the alkyl group and the aryl group are as defined above. An example of an arylalkyl group is benzyl. In one embodiment, the "scientific composition" refers to a therapeutically effective amount of live 56 200526202 sexual component, that is, a selective androgen receptor modulator (eg, egg dipper compound, and a pharmacological agent). An acceptable carrier or diluent. In one embodiment, a "therapeutically effective amount" refers to an amount that provides a therapeutic effect on a particular amount of money and investment. 5 Anything known to the skilled artisan A method of administering a pharmaceutical composition containing an sARM agent to a body, such as a parenteral method, a near cancer method, a transmucosal method, a transdermal method, an intramuscular method, an intravenous method, an intradermal method, and a subcutaneous method , Intraperitoneal mode, intraventricular mode, intracranial mode, intravaginal mode or intratumoral mode. 10 In one embodiment, the pharmaceutical composition is administered orally, and is thus formulated into a form suitable for oral administration. As a solid or liquid formulation. Suitable solid oral formulations include bonds, capsules, pills, granules, pills, etc. Suitable liquid oral formulations include solutions, suspensions, emulsions, milk Liquid, oil, etc. In one embodiment of the present invention, the arm 15 compound is formulated into a capsule. According to this embodiment, the composition of the present invention contains the SARM active compound and an inert carrier or diluent in addition It also contains a hard gelatin capsule. Furthermore, in another embodiment, the pharmaceutical composition is administered by intravenous, intraarterial or intramuscular injection of a liquid preparation. Suitable liquid formulations include 20 solutions, suspensions Liquid, emulsion, emulsion, oil, etc. In one embodiment, the pharmaceutical composition is administered intravenously, and is thus formulated in a form suitable for intravenous administration. In another embodiment The pharmaceutical composition is administered intra-arterially, and is thus formulated into a form suitable for intra-arterial administration. In another embodiment, the pharmaceutical composition is administered intra-muscularly 200526202, and is thus formulated A form suitable for intramuscular administration. Furthermore, in another embodiment, the pharmaceutical composition is administered topically to the surface of the body, and is thus formulated into a form suitable for topical administration. Suitable Bureau Formulations include gels, ointments, creams, lotions, drops, etc. 5 For topical administration, the SARM agent or its physiologically tolerable derivatives such as salts, esters, N-oxides, etc. , Prepared in the form of a solution, suspension or emulsion in a pharmaceutically acceptable diluent with or without a pharmaceutical carrier and administered. Further, in another embodiment, the pharmaceutical composition It is in the form of a suppository, such as a rectal suppository or a urethral suppository. Furthermore, in another embodiment, the pharmaceutical composition is administered by implanting a pill subcutaneously. In another

In embodiments, the pill provides controlled release of the SARM agent over a period of time. 15 20 In another embodiment, the active compound can be delivered in a carrier.] Moon-shell sunbeams (see Langer in Science 249, 1527-1533 "0 years"), Treat et al. In Lopez -Edited by Berestein and Fidler. Liposomes in Infectious Diseases and Cancer Therapy, Book B, pp. 353_365, United States = New York, Liss Company, published in brief years; the aforementioned L () pez · Essence, Book B, 317 -327 pages; see the whole of the same book as above). "Technology" such as "pharmaceutically acceptable carriers or diluents," are familiar to those skilled in the art. The carrier or diluent can be a solid or diluent used in a solid formulation, a liquid carrier or diluent used in a liquid formulation; a mixture of lice. Solid Carriers / Dilute_Including but secret from -Qing,-View powder (corn 58 200526202 powdered powder, pre-set knee starch),-a kind of sugars (lactose, sweet,-caramel), a fibrous substance (such as eating Said ... 庶 sugar, right ㈣, (H quasi), an acrylate (such as m-propion-like purpose),-, magnesium oxide, talc «mixture. 5 10-'Pharmaceutically acceptable injection for liquid formulations' Examples of aqueous or non-aqueous / cereals, suspensions, emulsions, or oils are examples of non-aqueous solvents such as propylene glycol / ethyl alcohol and organic compounds such as ethyl oleate. Aqueous carriers include water; aqueous solutions; emulsions or suspensions, including saline and buffered substrates. Examples of type 1 are petroleum, animal, plant or human origin.

Source oils such as peanut oil, soybean oil, mineral oil, olive oil: sunflower oil and cod liver oil.

Parenteral vehicles (for subcutaneous, intravenous, intraarterial or intramuscular injection) include sodium vaporized solution, Ringer's dextrose, dextrose and sodium vaporized, lactated Ringer's ( Ringer) fluid and qualitative oil. Intravenous vehicles include fluid and nutrient supplements, electrolyte supplements, and the like. Ringer's dextran 15 is the main ingredient. Examples include sterile liquids such as water and oils with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Generally, the preferred liquid carriers are water, saline, aqueous dextrose and related sugar solutions, and aliphatic diols such as propylene glycol or polyethylene glycol, especially for injectable solutions. Examples of oils are oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil and cod liver oil. In addition, the composition may further include a binder such as acacia, jade starch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl fluorene-based fiber Cellulose, polyvinylpyrrolidone); 59 200526202 disintegrating agents (such as corn starch, potato starch, alginic acid, silicon dioxide, cross-linked carboxymethyl cellulose sodium salt, cross-linked polyethylene ketone, guar beans Glue, sodium starch glycolate has various pH and ionic strength buffers (such as Tris HC1, acetate, and acid salt); additives such as albumin or gelatin to avoid adsorption to the surface; detergents (such as Tween 2〇, τ · η 80, F68, bile salt); protease inhibitors; surfactants (such as sodium lauryl sulfate), penetration enhancers; solubilizers (such as glycerol, polyethylene glycerol); Antioxidants (such as ascorbic acid, sodium metabisulfite, butylated hydroxyanisole stabilizers (such as transpropyl cellulose, transpropylmethyl cellulose); tackifiers (such as 10 Carbomer ), Colloidal silica, ethyl cellulose, melons Soybean gum); sweeteners (such as aspartame phenylalanine methyl @purpose, citric acid); preservatives (such as o-ethylmercury sodium thiobenzoate (Thimerosal), benzyl alcohol, henyl or propyl para_ Ik Basic 曱 fcc S purpose), lubricants (such as stearic acid, sodium stearate, polyethylene glycol, sodium lauryl sulfate); glidants (such as colloidal silica); plasticizers (such as benzene 15 Diethyl formate, triethyl citrate); emulsifiers (such as carbomer, hydroxypropyl cellulose, sodium lauryl sulfate); polymer coatings (such as Poloxamer (P (10 × x), or coatings and film-forming agents (such as ethyl cellulose, acrylate, polymethacrylate); and / or adjuvants. 2〇 In another embodiment, the pharmaceutical composition provided herein is a controlled release type composition, that is, the composition releases a sarm compound during a period of time after administration. The controlled release type or the sustained release type The composition includes a formulation located in a lipophilic reservoir (such as fatty acids, waxes, oils). In another embodiment, the composition is an immediate release composition, or The immediate release composition in all 60200526202 SARM compound after administration.

In another embodiment, the pharmaceutical composition can be delivered in a controlled release system. For example, the agent may be administered using intravenous infusion, implantable osmotic pumps, transdermal patches, liposomes, or other modes of administration. In a practical example, a pump can be used (see the previous article by Langer; Sefton in CRC

Crit · Ref · Biomed · Eng · No. 14 p. 201 (1987); Buchwald et al. Surgery No. 88 p. 507 (1980) B; Saudek et al. N. Engl. J. Med (Issue 321, p. 574 (1989)). In another embodiment, a polymerizable substance may be used. In another embodiment 10, a controlled-release system can be placed near the target of treatment, that is, the brain, so only a part of the systemic agent: g: (see Goodson in "Controlled-release Medicine Application '', Vol. 2, pp. 115-138 (1984). In the comprehensive review of Langer (Science, Vol. 249, pp. 1527_1533 (1990)), other controlled release systems are addressed. 15 The composition also includes the active substance in or on a granular formulation of a polymerizable compound such as polylactic acid, polyglycolic acid, hydrogel, or the like, or in liposomes, microemulsions, micelles, and monolayers. Or multilayer carrier, red blood cell shadow or protoplast. These components will affect the physical state, solubility, stability, release rate in vivo and clearance rate in vivo. 20 The present invention also encompasses polymers ( Such as poloxamer or poloxamine-coated granular composition, and coupled with antibodies, ligands or antigens directed against tissue-specific receptors or tissue-specific receptors Cognate coupling The invention also encompasses the use of covalently linked water-soluble polymers such as polyethylene 61 200526202 alcohols, copolymers of polyethylene glycol and polypropylene glycol, carboxyfluorenyl cellulose, dextran, polyvinyl alcohol, polymer Ethylene u is a compound modified by π ketone or polyproline. It is known that the modified compound exhibits significantly longer in blood after intravenous injection than the corresponding unmodified compound. Half-life 5 (Abuchowski et al. 1981 b. Newmark et al. 1981 b. Katre et al. 1981 b.) These modifications can also increase the solubility of the compound in aqueous solutions and eliminate aggregation Effect, improve the physical and chemical stability of the compound, and significantly reduce the immunogenicity and reactivity of the compound. As a result, the polymer 10 compound adduct has a lower frequency than the unmodified compound. Or lower doses can achieve the desired biological activity in vivo. The preparation of a pharmaceutical composition containing an active ingredient is well known in the art, such as by mixing, granulating or tabletting methods. Active treatment The ingredient book is mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. 15 For oral administration, SARM agents or physiologically tolerable derivatives such as salts, esters, N_ Oxides and the like are mixed with conventional additives such as carriers, stabilizers or inert diluents for the purpose, and converted into suitable dosage forms by conventional methods, such as lozenges; film-coated tablets; hard or soft gelatin capsules, Aqueous, alcoholic or oily solution. For parenteral administration 20 words, SARM agents or their physiologically tolerable derivatives such as salts, esters, N-oxides, etc. are converted into a solution, suspension Or emulsion, if desired, add the substances customary and suitable for the purpose, such as stabilizers or other substances. The active ingredient can be formulated in a neutral pharmaceutically acceptable salt form 200526202 and incorporated into the composition. Pharmaceutically acceptable salts include acid addition salts (formed with multi-monthly or amines from antibody molecules), which are formed with inorganic acids such as hydrochloric acid or acid, or with organic acids such as Formed by acetic acid, oxalic acid, tartaric acid, and sodium phenylacetic acid. Salts formed from free carboxyl groups can also be derived from inorganic compounds such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium oxide, or iron hydroxide, and derived from organic bases such as isopropylamine, triamidine Aminoamine, 2-ethylaminoethanol, tissue ammonium acid, procaine, and the like. For medical use, the salts of SARM are pharmaceutically acceptable salts. However, 'other salts may be suitable for use in the preparation of the compounds of the invention or 10 their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts, which can be obtained, for example, by combining a solution of a compound of the invention with a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, trans A solution of one of succinic acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid, or phosphoric acid is mixed and formed. 15 As used herein, "administration," the term refers to contacting a body with a SARM compound of the invention. If used herein, administration can be accomplished in vitro, i.e. in a test tube, or in vivo, i.e. This is done in a living organism, such as a human cell or tissue. In one embodiment, the invention encompasses the administration of a compound of the invention to an individual. 20 In one embodiment, the term "contact" refers to The SARM compound of the present invention is introduced into a subject undergoing treatment, and the SARM compound is allowed to come into contact with an androgen receptor (AR) in vivo. In one embodiment, the method of the present invention includes administering one as the sole active ingredient SARM compounds. However, 200526202 is also covered in the present invention.

A method for treating and / or preventing a bone-related disorder, comprising administering a sARM compound in combination with one or more therapeutic agents. The turtle turtle λ pleasure agent includes, but is not limited to: LHRH analogs, reverse anti-androgens, anti-estrogens, anticancer drugs, 5-alpha reductase inhibitors, aromatic ring invertase inhibitors, luteinizing hormone Agents acting through other nuclear hormone receptors, selective estrogen receptor regulators (SERM), lutein® g, estrogen, 1 &gt; £ 5 inhibitors, morphine dehydrate, bisphosphonates, and One or more additional eight eight &amp; 乂. Thus, in one embodiment, the method of the invention comprises administering the selective androgen receptor modulator (SARM) compound in combination with a LHRH class 10 analog. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a reversible antiandrogen. In another embodiment, the method of the invention comprises administering a SARM compound in combination with an anti-estrogen. In another embodiment, the method of the invention comprises administering a SARM compound in combination with an anticancer drug. In another embodiment, the method of the present invention 15 comprises administering a SARM compound in combination with a 5-00 ^ reductase inhibitor. In another embodiment, the method of the invention comprises administering a SARM compound in combination with an aromatic ring invertase inhibitor. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a progestin. In another embodiment, the method of the present invention comprises administering 20 SARM sub-compounds in combination with an agent that acts via other nuclear hormone receptors. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a selective estrogen receptor modulator (SERM). In another embodiment, the method of the invention comprises administering a SARM compound in combination with a luteal surface I. In another embodiment, the method of the invention 64 200526202 comprises administering a SARM compound in combination with an estrogen. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a PDE5 inhibitor. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a dehydrated morphine. In another embodiment, the method of the invention comprises administering a SARM compound in combination with a bisphosphonate. In another embodiment, the method of the invention comprises administering a SARM compound in combination with one or more additional saRMs. EXAMPLES Example 1 · 10 Experimental Design-1st to 1st M Animals were randomly assigned to each treatment group (n &gt; 10) outlined in the table below. Animals were assigned to certain groups and surgically removed ovaries (OVX) on day 1 of the experiment. Drug administration with Compound VI, Compound IX and Compound I, anti-androgens and / or DHT is performed immediately (ie on the day of ovarian removal) or 90 days after ovarian removal Performed to assess the ability of these compounds to inhibit osteolysis (immediate treatment) or stimulate bone formation (delayed treatment). The compounds investigated were administered daily by subcutaneous injection (0.25 ml) and continued until the 180th day of the experiment. Drug solutions were prepared by dissolving in ethanol and diluting with polyethylene glycol 300. The percentage of ethanol in all carriers 20 was the same and was determined based on the solubility of the test compound. &quot; Collect dual-energy X-ray absorptiometry (DEXA) images of the whole body up to 210 days after removal of the nest, and the description is in the table below. Measure bone mineral density (BMD), bone mineral content (BMC), bone mineral area 65 200526202 (BMA), fat-free weight (LBM), fat weight (FM), total body weight (TBM) and Subregional bone mineral density (BMD) of the lumbar spine and left femur. All animals were sacrificed on day 120 after the start of treatment. The femur and tibia were excised from the sacrificed rats for subsequent experiments. Five or more serum and urine samples were collected before or at the time of sacrifice, and used to determine the serum concentrations of osteocalcin, IL-6, and IGF-1 in each group of animals and the urine of deoxydine and creatinine Medium concentration.

66 200526202 Table 1: Experimental groups of 1 to 14 cases # Date of DEXA treatment for gonad status 1 Complete-0, 30, 60, 90, 120, 150, 180,210 2 Complete 1.0 mg / day of DHT Immediately Treatment # 0, 30, 60, 90 3 Complete 1.0 mg / day of compound VI immediately treated 4 Ovariectomy-0, 30, 60, 90 5 Ovariectomy 1.0 mg / day DHT immediately treated 0, 30, 60, 90 6 1.0 mg / day ovariectomy compound + 0.5 mg / Bicaiutamide immediate treatment 0, 30, 60, 90 7 0.1 mg / day ovariectomy compound immediate treatment 0, 30, 60, 90 8 Compound III treated with ovariectomy 0.3 mg / day immediate treatment 0, 30, 60, 90 9 Compound III compound treated with 0.5 mg / day ovariectomy immediately treated 0, 30, 60, 90 10 Ovariectomy 0.75 mg Compound VI treatment per day immediately treated with 0, 30, 60, 90 11 Ovariectomy 1.0 mg per day Compound VI treated immediately 0, 30, 60, 90 12 3.0 mg compound removed with ovariectomy immediate treatment 0, 30, 60, 90 13 Complete 1.0 mg / day DHT delayed treatment 0, 90, 120, 150, 180, 210 14 1.0 mg / day of Compound V Delayed Treatment 0, 90, 120, 150, 180, 210 15 Ovariectomy-0, 90, 120, 150, 180, 210 16 Ovariectomy 1.0 mg / DHT Delayed Treatment 0, 90, 120, 150, 180 , 210 17 Compound VI with 1.0 mg / day ovariectomy + 0.5 mg / Bicalutamide Delayed treatment 0, 90, 120, 150, 180, 210 18 Compound VI with delayed 0.1 mg / day delayed Treatment of 0, 90, 120, 150, 180, 210 19 Delayed treatment of compound VI with ovariectomy 0.3 mg / day 0, 90, 120, 150, 180, 210 20 Delayed treatment of compound VI with ovariectomy 0.5 mg / day 0, 90 , 120, 150, 180, 210 21 Delayed treatment of compound VI with OVX 0.75 mg / day 0, 90, 120, 150, 180, 210 22 Delayed treatment of compound VI with OVX 1.0 mg / day 0, 90, 120, 150 , 180,210 23 Ovariectomy 3.0 mg / day delayed treatment of compound VI 0, 90, 120, 150, 180,210 24 Ovariectomy 1.0 mg / day delayed treatment of compound IX 0, 90, 120, 150, 180,210 25 Ovariectomy 1.0 Mg / day of compound XI immediately treated 0, 90, 120, 1 50,180, 210 26 Delayed treatment of compound IX with 1.0 mg / day ovariectomy 0, 90, 120, 150, 180, 210 27 Delayed treatment of compound XI with 1.0 mg / day ovariectomy 0, 90, 120, 150, 180, 210 67 200526202 The second case of compound VI in rats with osteoporosis and fatigue prevention + epiphyseal material density (BMD) reduction materials and experimental methods (No. 5 from Harlan Corporation (Indianapolis, Indiana, USA) (Indianapolis) purchased female Sprague-Dawley rats. One cage for every three animals, and free access to tap water and commercial rat food (Harlan Teklad 22/5 Prey Animal Food-8640), and 12 hours of light- Dark week 10 issues. This experiment was reviewed and approved by the Public Laboratory Maintenance and Use Committee of Ohio State University. Experimental design Animals underwent ovariectomy (0νχ) or sham surgery at 23 weeks of age, and were then assigned to 12 treatment groups (Table 2) and each group had 10 animals and 15 animals, receiving different amounts of Compound VI, other therapies, or not receiving treatment, as described in the results section. Animals undergoing sham surgery are referred to herein as "complete," to show that their nests have not been removed. During the study period, 5 animals died for non-drug related reasons. Therefore, groups 6 and 10 each consisted of 9 Animals were made up, and Group 4 was made up of 8 animals. The drug solution was prepared daily by dissolving the drug in DMS0 and diluting with polyethylene glycol 20 3-> EG300. A subcutaneous injection of a volume of 0.20 ml was administered daily for a total of 120 days. White 200526202 Table 2: Groups 2 to 8 of the experimental group No. VI compound (mg / day) DHT (mg / day) ) Bicalutamide (mg / day) 1 Complete — — — 2 Complete — 1.0 — 3 Complete 1.0 — — 4 Ovariectomy — — — 5 Ovariectomy — 1.0 — 6 Ovariectomy 0.5 — 1.0 7 Excision Ovarian 0.1 — — 8 Ovariectomy 0.3 — — 9 Ovariectomy 0.5 — 10 Ovariectomy 0.75 — — 11 Ovariectomy 1.0 — One 12 Ovariectomy 3.0 — —

After a whole-body DEXA scan on day 120, groups 2 to 12 were sacrificed, and the lumbar spine, femur, and tibia were excised, and soft tissues were removed. At the end of the study 整 5 The entire control group (group 1) was also used as the control group for the concurrent delayed treatment study described in 9 to 13 cases. Therefore, group 1 died on 210 days. Measurement of physical parameters · Using small animal software (Lunar enCore's version 6.60.041 'edition), the whole body bone mineral density (BMD) was measured by DEXA (Lunar 10 Prodigy ™ of GE) on the 0th and 120th days. ), Fat mass percentage (FM), body weight (BW), bone mineral content (BMC), bone mineral area (BMA), and lean muscle mass (LM). Simultaneously, 700 series Ohaus animals 69 200526202 were used on a three-beam scale (Florham Park, New Jersey, USA), and the weight was measured by a standard weight method. For the DEXA scan, the animals were anesthetized with ketamine: toluene sigmazone (87:13 mg / kg) and placed in a supine position. Whole-body data were obtained by selecting an area covering the entire animal as the area of inquiry during data 5 processing. The parameters used and reported here are those that have the highest sensitivity to estrogen discontinuation (that is, the one with the largest difference between the intact control group and the ovariectomized control group) to focus our analysis On the most sensitive hormonal measurement with a large dynamic range. 10 The compound VI (group 11) taken from the ovariectomy + 1.0 mg / day, the compound VI (group 12) taken from the ovariectomy + 3.0 mg / day, and the indole removed + 1.0 mg / Day of DHT (group 5), ovariectomy control group (group 4), compound + 1 mg / day of compound VI (group 3) and the right femur of the complete control group (group 1) were sent to Skeletech Inc. (Bothell, Washington, USA), 15 to perform peripheral quantitative computed tomography (pQCT) analysis and biomechanical tests. A Stratec XCT RM and related software (software version 5.40C of Stratec Medizintechnic GmbH, Pforzheim, Germany) were used to perform a pQCT scan of the femur. At the same time, analyze the central and distal regions of the femur. The length of the femur was determined using a scout scan pattern, and the mid-bone area (50% of the femur length) and the distal area (20% of the femur length from the distal end) were selected as the investigation areas. An analysis was performed using a 0.5 mm section perpendicular to the long axis of the femur. Measure the total bone mineral content, total bone area, total bone mineral density, cortical bone mineral content, cortical bone area, cortical bone mineral content in the mid-femoral backbone 70 200526202 material density, cortical thickness, periosteal perimeter ( Circumference) and endosteal perimeter. Measure the total bone mineral content, total bone and collaterals, surface sowing monthly mouth to defecation, overall bone mineral density, bone mineral content of trabeculae, bone micropoles &amp; company ^ moon area in distal femur And bone mineral density of trabeculae. 5 After the QCT analysis ’, use a three-point bending test towel to remove muscle

Of the entire femur. Using an electronic caliper, measure the front-to-back diameter (APD) (in millimeters) at the midpoint of the femoral shaft. In an Instron test) mechanical test machine (Instrcm 4465 converted to 5500) (Canton, Washington, USA), the femur was placed in a three-point bend The lower position of the 10-position device is supported with the front side of the femur facing downwards. The length (L) between the lower supports is set to M mm. The upper loading device is aligned with the center of the femoral shaft. The load was placed at a constant displacement rate of 6 mm / min until the femur was broken. This mechanical testing machine directly measures the maximum load (Fu) (in Newtons), stiffness (S) (in Newtons / mm) and the absorbed energy 15 (w) (in millijoules). During the internal femoral backbone, borrow

The inert shaft moment area 力矩 (unit: mm 4) is calculated by the software. Calculate the stress (d) (in Newtons / mm2), elastic modulus (E) (in Mpa), and toughness (T) (in millijoules / mm3) by the following equations: stress p (Fu L * (a / 2)) / (4 * I), elastic modulus ε = s * L3 / (48 * I); and toughness τ = 20 3 * W * (APD / 2) 2 / (L * I ). Selective analysis Statistical analysis was performed by single factor analysis (AN0VA) of the number of variations. If the P value is less than 0.05, it is considered to have a statistically significant difference. 71 200526202 Rats were assigned to one of 12 treatment groups. Groups 4 to 12 underwent ovariectomy on day 0 of the study, while groups 1 to 3 were intact rats. Groups 7 to 12 received a daily dose of compound VI by subcutaneous injection of [; 0.3, 0.05, 0.05, 1.0, 3 mg / day, respectively. Groups 1 and 4 were the complete control group (ie, the ovaries were not removed) and the negative control group with ovaries removed, and they only received DMSO. Groups 2 and 5 (whole rats and ovariectomized rats) received dihydrotestosterone (DHT) (1 mg / day) as a positive control group. Group 3 was intact rats that received 10 mg / day of compound VI. Group 6 was ovariectomized rats that received a compound VI 10 of 0.5 mg / day and an anti-androgen Bicalutamide of 1.0 mg / day to show the experience of the compound ¥ 1 The effects of androgen receptor regulation are relative to effects not related to the androgen receptor. Bone mineral content (BMC) was measured on days 30, 60, 90 and 120. Figure 1 shows the whole body bone mineral density 15 (BMD) at day 120 in all groups. As expected, the bone mineral density of the ovariectomized rats was significantly lower than that observed in the intact control group at day 120. To bone mineral density (0.214 g / cm2). Compound treatments with doses greater than 0.01 mg / day 'in ovariectomized rats are partially (ie, the bone mineral density is significantly greater than that of the control group removed from the nest) or completely (ie, the bone mineral density and There was no significant difference in the complete control group (20)) to prevent the reduction of bone mineral density in bones. DHT completely maintains bone mineral density in resected Indian nest rats. However, &apos; DHT caused a significant reduction in bone mineral density in intact large breasts; and compound VI therapy maintained bone mineral density in intact rats in the intact control group. If simultaneous administration of the anti-androgen bicalutamide 72 200526202 (Bicalutamide), the effect of the compound VI is partially prevented, which shows that the response system of the bone to the compound VI is partially regulated by the androgen receptor. Thus, the VI compound prevents a decrease in bone mineral density in ovariectomized rats. 5 Figure 2 shows the DEXA analysis results of the excised L5-L6 spine. Although the mineral density of the vertebral bone of the atmosphere in the control group was significantly reduced during the experiment, compound VI therapy had a dose-dependent bone-protecting effect; 3 mg / day of compound VI was completely prevented and 0.05 The mg / day compound VI partially prevents bone loss caused by ovariectomy. Ovariectomized rats exhibited bone mineral density higher than those of control group rats administered with the compound VI at 0.1, 0.3, and 0.75 mg / day, but the difference was not statistically significant. . If Bicalutamide is administered at the same time, Part V will be partially prevented; [The bone-protecting effect of the compound. In contrast to the vi compound, DHT therapy did not prevent bone loss in the L5-L6 spine in ovariectomized rats. In intact rats, compound VI had no effect on bone mineral density, while DHT therapy significantly reduced bone mineral bifurcation to a level similar to that of the control group with ovariectomy. Compound VI prevents the reduction of bone mineral density caused by ovarian resection in the L2-L4 spine (Figure 3), the fourth region of the femur (Figure 4), and the proximal femur (Figure 5). Therefore, the VI compound prevents the reduction of bone mineral density in the L2-L4 and L5-L6 spines caused by ovarian removal. The findings of this example show that the V] [compounds prevent specific reductions in bone mineral density caused by ovarian removal at several specific locations throughout the body and the body. Therefore, the selective androgen receptor modulator (SARM) is suitable for preventing bone loss caused by hormone factors such as menopause. Compound VI in the third case prevents the loss of cortical bone due to osteoporosis and it is known in the individual. The cortical thickness (CT) of the mid-femoral diaphysis of the rat from the second case was measured by 5 Figure 6). Ovariectomized rats have lower cortical density than intact rats. Although both compound VI and DHT prevented a decrease in cortical thickness, the cortex thickness was higher in the group treated with compound VI than in the group treated with DHT. In addition, intact rats receiving Compound VI and 10 ovariectomized rats showed a significant increase in cortical thickness above the level of the intact control group. The cortical content (CC) of the central femoral shaft was also evaluated (Figure 7). In the ovariectomized control rats, a significant decrease in cortical content from 10.3 to 8.8 mg / mm was observed. Compound VI completely prevented the decrease in cortical content, while 15 DHT only partially prevented the decrease in cortical content. In addition, the group receiving Compound VI at 3 mg / day exhibited an increase in cortical content, which was higher than that of the intact control group. The periosteal circumference (PC) of the mid-femoral diaphysis was also measured (Figure 8). Although the circumference of the ovariectomized rats was reduced, the treatment with Compound VI prevented the reduction completely. Cortical bone mineral density (CD) of the mid-femoral shaft was measured by pQCT. Compound VI completely prevents a decrease in the mineral density of the cortical bone caused by ovarian removal, while DHT only partially prevents a decrease in the mineral density of the cortical bone. Compared to ovariectomized and intact control rats, intact rats receiving compound No. 200526202 showed an increase in cortical bone mineral density. Cortical thickness (CT), cortical content (CC), periosteal circumference (ρ0), and cortical bone mineral density (CD) are markers of cortical bone content, density, and strength. Therefore, related compounds of the VI compound in ovariectomized rats The discovery of these stable markers 5 shows that selective androgen receptor regulators (SARMs) exhibit their bone-stabilizing properties in cortical bone. In addition, the findings of this experiment show that SARMs increase osteoporosis (ovariectomy) ) And osteoporosis in non-osteoporotic individuals. Case 4 · 10 Compound VI prevents the loss of ossicles caused by sacral osteosynthesis and increases the mass of trabecular bone in healthy athletes. The mineral density of the trabecular bone in the distal femur of 2 rats (Figure 9). After ovarian removal, a significant decrease in trabecular bone from 735 to 609 mg / cm3 was observed, which can be achieved by Compound 1 was prevented with DHT by 15 points. In addition, Compound VI treatment caused intact trabecular mineral activity in intact rats to a level significantly toward one of the intact control group. The findings of this example show that Selective androgen receptor Modulator Lu (SARM) highlights its bone-stabilizing properties in trabeculae. In addition, these findings show that SARM increases osteoporosis (nest resection) and non-osteoporosis. Bone trabeculae in 20 individuals # MJM. 'Cover YL metal compounds strengthen bones in osteoporosis and also measure the biomechanical strength of the femur (Figure 10). The femoral biomechanical strength of the rats in the household group removed after the nest was significantly reduced, It can be completely prevented by 75th Compound No. 20052005202 VI and DHT therapy. Compound VI does not show effects in intact rats. In addition, the 'compressive strength (cs) of rat bones is measured in this case. Measurement of the L5 spine (Figure 11). Although ovariectomy did not cause a significant decrease in compressive strength, Compound VI increased compressive strength in both intact and ovariectomized rats. The findings of this example show that selective males Hormone receptor regulator (SARM) strengthens bones in osteoporosis (ovariectomized) and non-osteoporotic individuals. 10 6th case of VI gold. Increase bone mineral content in osteoporotic individuals ... In the experiment described in Example 2, a time- and dose-dependent increase in bone mineral content (BMC) was observed in all groups treated with compound ¥ 1; at day 120, relative In the ovariectomized control rats, 15 words' increased by 22.9, 26.0, 28.5, 30.5, 30.0, and 40.1% in groups 7 to 12 (Figures 12A-B). The increase in bone mineral content of DHT was larger than Small (15%). At the time point of day 30, rats treated with compound VI, but not rats treated with DHT, exhibited an increase in bone mineral content (Figure 13). Therefore, 'VI The compound increases bone mineral 20 content in ovariectomized rats, which shows that the selective androgen receptor modulator (SARM) increases bone mineral content in osteoporotic individuals. The 7th case of the YJ chemical substance reduced the fat mass in osteoporotic individuals. 76 200526202 5 10 15 20 Value + chemical = wealth = flat clock weight is 26 out of 7 grams (average n = 12〇) ° 5 Weight (Figure 14). The weight of all the groups removed from the nest was large = whole =, the group's significant effect on the growth of rats. In the group of 3.0 mg / day of the compound VI, a weight gain was observed. In the intact rat, 5 compared to the intact control group, bribery resulted in weight gain; and in comparison with the removed indole and intact control group, the &apos; VI compound caused a significant weight loss. On day 120, the percentage of fat mass (rigid) was measured by ΜχΑ (Fig. Μ). The control group that removed the nests showed significantly higher fat mass than the intact Ί · 〃, indicating that estrogen deficiency affects the body composition. The ^ th compound therapy reduces fat mass in a dose-dependent manner, and the fat mass level of the group receiving 3.0 mg / day is comparable to that of the intact control group; if administered concurrently with carotamide (Biealutamide), prevents the amount of lin # from the Diguan compound to decrease. Lithotherapy increased fat mass in both intact and excisional rats. The fat mass values were higher than those in the complete control group but lower than those observed in the ovariectomized control group. Relative to the intact control group, intact rats receiving the Dizhou compound exhibited a decrease in fat mass. Corresponding changes in lean muscle mass percentage were observed in all groups. Therefore, Dipyridine prevents the increase in fat mass caused by ovarian removal.

The findings of this example show that the selective androgen receptor modulator (SARM) prevents an increase in the lean muscle mass / fat mass ratio in individuals with osteoporosis. 77 200526202 The eighth case of the first YU Dose I do not increase the strength of osteocalcin in individuals with osteoporosis. Osteocalcin was measured in serum samples taken before sacrifice. Removal of Indigo increases osteocalcin levels. Compound VI and DHT treatment can restore this level to the level observed in unexcisional ovariectomized controls (Figure 16). In summary, the 2nd to 8th cases showed that the vi compound inhibited the loss of cortical bone and trabecular bone, inhibited the reduction of bone strength, and inhibited the increase in fat mass in osteoporotic individuals. Furthermore, Compound VI also exhibits many of these properties in non-osteoporotic individuals. Furthermore, in most cases, the positive effect of the VI compound can be compared with or better than that of DHT. Therefore, the present invention shows that: (a) 'selective androgen receptor modulator (SARM) has the effect of promoting osteogenesis in the presence or absence of osteoporosis, and (b) SARM has the ability to combat osteoporosis. Anti-erosion effect. Materials and experimental methods of reducing the degree of IMD (BMD) of Korean bone marrow in the 9th case of osteoporosis in individuals with osteoporosis 2. The same treatment as described in the example; however, 'in the case of this example, the treatment was started on the 90th day after the Indo-resection operation. Mice were sacrificed on day 21 and analyzed as described in the second example. Results 78 200526202 As shown in Figure 17, the body bone mineral density (0.197 g / cm2) of the control group was lower than that of the intact control group (0.212 g / cm2). In the dose groups of 0.3, 0.5, 0.75, 1.0, and 3.0 mg / day, the VI compound significantly reversed the decrease in bone mineral density to 50-204, 0.209, 0.206, and 0.205, respectively. , 0_205 and 0.206 g / cm². In contrast, DHT did not restore bone mineral density. Neither DHT nor the VI compound increased bone mineral density in intact animals. The VHb compound increased the bone mineral density to 0.214 g / cm2 in a non-statistically significant amount in the intact control group; on the contrary, 〇ΤT reduced the bone mineral density to 0.205 10 g / cm2. Animals receiving both Compound VI and Bicalutamide are not different from animals receiving Compound VI only. The &apos; VI compound therefore reverses the decrease in bone mineral density in individuals with osteoporosis. As with bone mineral density throughout the body, excision of the ovaries negatively affected bone mineral density in the L5_L6 15 spine, resulting in a decrease from 0.234 g / cm2 in intact animals to 0192 g / cm2 in the ovariectomized control group (No. 18 Figure). The bone mineral density of L5-L6 in the groups receiving 30 mg / day and 0.3 g / day were completely restored or significant relative to the control group of the ovaries-removed animals. The bone mineral density increased by 20 plus but did not reach statistical significance. Similarly, DHT therapy partially restores L5-L6 'mineral density in oviposited animals. Compound V did not &amp; L5_L6 bone mineral density in whole animals, while DHT caused L5 to L6 mineral density to be significantly reduced to levels similar to those of the ovariectomized control group. Treated with the VI compound and Bicalutamide 200526202 = L5_L6 bone of the object "Wide material density, as in animals treated with only the same amount of VI character" _ 人物 弟 I 化 簌 物化 物The mineral density of L5_L6 bones collected by private electric inspection showed significant differences. In the femoral mineral rate ... ',,,, and the difference chart), however, similar results were observed in this situation. ⑷9 Chu compound doses at 0.1, 0.75, and 3.0 mg / day 6 reached Lh Zhen New. As a result, the VI density of this substance decreases. The result of reversal of the bone mineral regulator (SARM) caused by ovarian removal showed that the 'selective androgen receptor was reduced by 10 degrees. Delay the treatment until the bones are clear ... The heart mineral shellfish is started after the occurrence of M pine, so that the activity of the antibasal activity should not be affected—cause Γ: = synergistic activity. Therefore, the osteosynthetic activity is: 2 At least one mechanism of increasing bone mass in moonbeam and non-osteoporotic individuals.

The cortical content (cc) of the central femoral shaft of the rat in the eighth case was measured. The cortex content of the removed and nested rats decreased from 1G.3 mg / mm to 8.9 mg / mm. Dose of compound VI of 1.0 and 3.0 mg / day, respectively, partially reversed the decrease in cortical content by ㈣ mg / pen meter) and completely (10.i mg / mm). DHT completely restored the cortical content to 9.9 mg / mm. Cortex thickness (CT) decreased from 0.72 mm to 0.66 mm as a result of oviposition; this reduction was significantly reversed in several groups treated with compound VI (Figure 2). Similar to the cortical content, the periosteal circumference (pc) decreased to 11.45 mm from 11.98 mm after the ovaries were removed; The reduction phenomenon was completely reversed to 12 06 mm and 12.21 mm (Figure 22). DHT therapy caused a small, non-statistically significant increase to 11.84 mm. The results of this example show that selective androgen receptor modulator 5 (SARM) can reverse cortical bone loss due to osteoporosis. Case 11 Compound VI reverses trabecular flow in individuals with osteoporosis.% Also, the bone mineral density of trabecular bone was measured at the distal femur (Figure). After excision of the ovary, the trabecular bone loss of the distal femur was obvious. Lu 10 DHT and compound VI partially restored bone mineral density of trabecular bone, showing that selective androgen receptor regulator (SARM) can partially reverse trabecular bone loss due to osteoporosis. Reversal of bone weakening in the twelfth individual with pine disease 191 Newton. Treatment with 丨 m and 30 mg / day compound νι increased the maximum load to 217 Newtons and 2 丨 5 Newtons, respectively. These values are compared with the complete control, and are combined ... The difference shows that the selective androgen receptor regulator 20 (Jail M) can reverse the bone weakening caused by osteoporosis. · Therapy increased the maximum load to 214 Newton. ^^ In order to eliminate the ovaries, the weight of the rat in the eighth case increased from 308 grams to 336 81 200526202 grams, and was further increased in a dose-dependent manner by the compound νι (Figure 25). For example, 〇_1 and 3.0 mg / day of compound VI treated groups averaged 350 grams and 381 grams, respectively. The weight of intact animals treated with compound VI was the same as that of the intact control group; while in intact animals 5 DHT therapy caused an increase in body weight to 357 grams. The percentage of fat mass in the rats was also evaluated. In the ovariectomized control group, the fat mass increased from 29% to 41%. In all dose groups, compound VI therapy Cause low fat mass In the ovariectomized control group, although the difference in some dose groups was not significant (Figure 26); a decrease was also observed in DHT therapy. 10 If Bicalutamide and Compound VI were administered simultaneously , Then partially eliminate the positive effect on fat mass seen in the compound VI treatment itself. For intact animals, the compound VI and D Η treatment caused a 2% reduction in fat mass and an 8% increase in fat mass. The findings showed that: ⑻ selective androgen receptor regulator 15 (SARM) can reverse the increase in fat mass due to osteoporosis; and (b) SARM can increase the body mass of individuals with osteoporosis. In summary, Section 9 The findings in 13 cases show that SARM can reverse the decrease in bone mineral density, loss of cortical bone and trabeculae, bone weakening and increase in fat mass in osteoporosis individuals. Only added later, the findings of these examples determine the synthesizing activity of compound VI, not the anti-erosion activity. These findings confirm the results of cases 2 to 8 and confirm SARM Anti-osteoporosis (a) osteosynthetic activity and (b) protective activity. Case 14 82 200526202 Comparison of Cap VI also with Articles IX and X! At the same time, the effect of compound ¥ 1 on bone growth and maintenance in the ovariectomy mode was compared with two structural analogs of compound VI, in which the p-nitro substituent of the A ring was replaced by 5 Substituted by a cyano substituent and the p-acetamido substituent of the B ring by a p-fluoro substituent (the compound) or a p-chloro substituent (the X: [Compound]. The compound was administered immediately after the ovaries were removed, and 90 days after the ovaries were removed. Rats were analyzed as described in 2 to 13 cases. 10 Figures 27 to 28 show the results of the immediate treatment group at day 120. As expected, bone mineral density was significantly lower in ovariectomized animals than in the intact control group at day 120. Sections VI, ιχ and the compound prevent the bone mineral density of the body from decreasing (Figure 27). The bone mineral density of the L5-L6 spine was also assessed. Ovariectomized vehicle reduced bone mineral density of animals in group 15 by a significant amount (Figure 28). The 1 mg / day doses of compounds VI, IX and XI all partially prevent bone loss caused by Indo-resection, but not DHT. Compound X1 has the largest effect on bone mineral density in the whole body and U_L6 spine, although this effect is not statistically different from the estimated addition of other selective androgen receptor modulators (SARMs). In intact animals, DHT treatment resulted in a significant reduction in bone mineral density to a level similar to that of the control group with ovariectomy; intact animals with the first compound had similar bone mineral density to the intact control group. These results show that, similar to Compound VI, Dihan and Yan compounds are powerful selective androgen regulated by II regulators (SARM), and they show — 200526202 bone-protection effect, and can be applied to treat muscle wasting and osteoporosis disease. Figures 29 to 30 show the bone mineral density study at day 210 in the delayed treatment group. Ovariectomy significantly reduces bone mineral density throughout the body, which can be partially prevented by compounds VI and DHT, but not compounds IX or XI (Figure 29). In the case of the L5-L6 spine, DHT therapy cannot prevent a decrease in bone mineral density (Figure 30). In intact animals, DHT caused a significant reduction in bone mineral density, which was not the case for compound VI. The mean weight of all immediate treatment groups was 262 ± 3 grams (mean ± SD). During the study period, all animals gained a significant amount of body weight (Figures 31 to 10), and excision of the ovaries caused further gains. Treatment with compounds IX and XI resulted in a further increase in body weight over the intact or ovariectomized control group. In intact animals, DHT therapy caused a further increase in body weight when compared to the intact control group, but not with compound VI. Similar results were observed in the delayed treatment group (Figure 32). 15 Resection of the ovaries resulted in an increase in fat mass and further increase with treatment of compounds IX and XI (Figure 33). However, this increase was significantly lower than that observed in the case of Compound VI. DHT therapy increased fat mass in intact and ovariectomized animals to levels higher than the intact control group but lower than those in the control group. Administration of gamma-a can reduce fat mass in intact rats. In the delayed treatment group, there was no significant difference between any of the treated oophorectomy groups and the oophorectomy control group (Figure 34). The results presented in this example show that the bone-protection effect is not unique to compound VI, and other selective androgen receptor regulators (SARMs) also exhibit this effect. Fifteenth experimental setting ~ 5 15 20 Animals were randomly assigned into 7 groups of venous catheters and administered intravenously (1.v. cardiac preparation-suitable MM is called Li ⑴ 5, 5, 10, and 30 mg / kg). Product delivered dose = give / solution, whereby the dose is delivered in a final volume measurement of G.2 to g.3 ml. It is based on the preparation of a double-liter liter injection benefit in the early stage, so as to make the volume three times the volume of the sterilized two :: after: with-the entire portion (oral gastrointestinal administration method, technique ... partial; water rinse guide #. Through the selection of 10 mg / m2 of the middle product dose 0, before the clinical conversion of the dose, it is a representative dose range .... The compounds used in the study of kingship and toxicity are in the technology of 0.5, 1, 10 and The average maximum plasma concentration of the VI compound reached at a dose of 30 mg / kg intravenously was 6, 2.3, 28, and 168 μg / ml, respectively. It was used to disperse the amount of diguanide compound (G.45 liters / Kg), which is slightly lower than the total body water volume (G.67 liters = liters / = ^). The doses of 0.5 mg / kg, i mg / kg and 10 mg / kg ^ ° / month removal effect (CL) is quite constant The ground was maintained at 1.92, 2.12, and j 52 ml / min · kg. However, the dose of the third compound of 30 mg / kg ^ had a lower clearance (CL) (1.00 ml / min. Kg, p &lt; 0.05). Because below the dose of 10 mg / kg, the area under the plasma concentration-time curve is proportional to the increase of 85 200526202 (AUC). However, At an intravenous dose of 3G mg / kg, the plasma concentration "the area under the line (in terms of) increases in a disproportionate manner to 29 mg · min / ml. The number of excretion from the urine is not significantly less than 0.15 % Of the drug is excreted in an unaltered form, which shows that the effect of excluding VI compound in an unaltered 5 form is negligible after the VI compound after a dose of ￥ 0 ^ 10 and 30 mg / kg Tl / 2 of 154, 182, 223, and 316 minutes, respectively. Because the clearance is reduced, MRT has been reduced from 0.5

222 and 240 minutes with a dose of 1 mg / kg 'increased to 305 and 423 minutes with a dose of iv and mg / kg. 10th after oral (P.O.) dose

After oral (ρ ·.) Doses of 1, 10 and 30 mg / kg, the average maximum plasma concentrations of the vi compound reached were 14, 14, and such as μg / ml, respectively. For doses of 1, 10, and 30 mg / kg, the time to maximum plasma concentration (Tmax) was 48, 84, and 336 minutes, respectively. Compound VI is fully bioavailable at doses of 1 and 10 mg / kg. However, after the 30 mg / kg dose was administered, the bioavailability of the% compound was reduced to 57%. After administration of doses of 1, 10, and 30 mg / kg, butane 1/2 of Compound VI was 203, 173, and 266 minutes, respectively. Skilled artisans will appreciate that the present invention is not limited to those specifically shown and described above. On the contrary, the scope of the present invention is defined by the scope of the following patent applications: I: Brief description of the drawing 3 Figure 1: Whole body bone mineral density (BMD) at the 120th day ]). a = P &lt; 0.05 relative to the 86 200526202 control group in which Yinchao was removed; b = P &lt; 0.05 relative to the complete control group. Figure 2: Bone mineral density of the lumbar spine (L5-L6) at day 120 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. 5 Figure 3: Bone mineral density of the lumbar spine (L2-L4) at day 120 (standard error of mean soil measurement). Figure 4: Bone mineral density at the 120th day of femoral zone 4 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. 10 Figure 5: Bone mineral density of the proximal femur at the 120th day (mean standard error of soil measurement). Figure 6: Cortical thickness of the mid-femoral shaft at day 120 (mean standard error of soil measurement). a = P &lt; 0.05 vs. control group with ovariectomy; b = = P &lt; 0.05 vs. intact control group. 15 Figure 7: Cortical content of the central femoral shaft at day 120 (mean standard error of soil measurement). a = P &lt; 0.05 vs. control group with ovariectomy; b = P &lt; 0.05 vs. intact control group. Figure 8: Periosteum perimeter of the diaphysis of the middle femur at day 120 (mean standard error of soil measurement). a = P &lt; 0.05 vs. control group 20; b = P &lt; 0.05 vs. intact control group. Figure 9: Bone trabecular density of the distal femur at day 120 (mean ± standard error of measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 10 · Maximum femoral load at day 120 (average soil measurement standard 87 200526202 quasi error). a = p &lt; 0.05 relative to the ovariectomized control group; b = p &lt; 0.05 relative to the intact control group. Figure 11: Compressive strength of L5 spine at day 120 (standard error of mean soil measurement). 5 Figure 12: (A) The percentage of bone mineral content (BMC) at day 120 crosses. (B) Time history of changes in bone mineral content. Data are presented as standard errors of mean soil measurements. Panel U: Percent change in bone mineral content (BMC) at day 30 (mean ± standard error of measurement). 10 Figure 14: Body weight at 120 days (mean + standard error of measurement). a &gt; P &lt; 0.05 vs. ovariectomized control group; b = p &lt; 〇_〇qa for intact control group. Figure U: Fat mass percentage at 120 days (mean ± standard deviation measured). a = P &lt; 0.05 relative to the control group with ovariectomy; b = p &lt; 150.05 relative to the intact control group. Figure 6. Serum osteocaicin level (standard error of mean soil measurement) on day 120. a = P &lt; 0_05 relative to the control group with ovariectomy; b ^ P &lt; 0.05 relative to the complete control group. Figure 17: Whole body bone mineral density on day 210 (mean ± 20 standard error of measurement). a = P &lt; 0.05 relative to the control group with resection of Indigo; b == p &lt; 0.05 relative to the complete control group. Figure 18: Bone mineral density of lumbar spine (L5-L6) at day 210 (standard error of mean soil measurement). a == P &lt; 0.05 relative to the control group with ovariectomy; b ^ P &lt; 0.05 relative to the complete control group. The complete control group was sacrificed on day 210 of 200526202. Fig. 19: Bone mineral density in femoral zone 4 on day 210 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. The complete control group was sacrificed on day 5 210. Figure 20: Cortical content of the central femoral shaft at day 210 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 21: Cortical thickness of the mid-femoral diaphysis at day 210 (mean 10 standard error of soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 22: Periosteum perimeter of the diaphyseal shaft of the femur at day 210 (standard error of mean soil measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. 15 Figure 23: Bone trabecular density of the distal femur at day 210 (mean ± standard error of measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 24: Maximum femoral load measured by three-point bending on day 210 (mean ± standard error of measurement). a = P &lt; 0.05 relative to the control group with 20 nests of eggs removed; b = P &lt; 0.05 relative to the complete control group. Figure 25: Weight on day 210 (mean + standard error of measurement). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the complete control group. Figure 26: Fat mass percentage at day 210 (mean soil measurement 200526202 standard error). a = P &lt; 0.05 relative to the ovariectomized control group; b = P &lt; 0.05 relative to the intact control group. Figure 27: Whole body bone mineral density on day 120. a = P &lt; 0.05 relative to the control group with ovariectomy; b = P &lt; 0.05 relative to the complete control 5 group. Figure 28: Bone mineral density of L5-L6 spine on day 120. a == P &lt; 0.05 relative to the control group for ovariectomy; b = P &lt; 0.05 relative to the complete control group. Figure 29: Whole body bone mineral density on day 21o. a = p &lt; 〇 is still 10 relative to the control group with resection of Indigo; b = p &lt; 005 is relative to the complete control group. ..., Figure 30: B5 mineral density of L5_L6 # vertebra at day 21. &amp; P &lt; 0.05 relative to the control group with resection of Indigo; b = p &lt; 0.05 relative to the control group. , 15 20 Figure 31: Weight on day 120. Control group of p nests; 4 &lt; Clear eyes for complete Z for removal of Indigo on day 2ig_ ° a = p &lt; G.G5 vs. control group of removed indigo nests, b = P &lt; 〇. () 5 vs. Complete control group. Figure 33. Fat mass percentage at day 120. a = for the resection of the contralateral rib; b = p · 05 phase with phase n 0 · 05 relative to the complete control group. . Fat mass percentage on day 210. a = p Symbol description] = two for complete comparison: (none) 90

Claims (1)

200526202, applied for patent Fangu ... 1. A method for treating a person suffering from Yijin; ^ ea ea ganoderma-related disorders, which includes the following: (SARM) compound or- A pharmaceutically acceptable salt, hydrated I oxide, or any combination thereof, is used to treat a subject suffering from a disease. _ The method described in item 1 of the January patent, wherein the osteogenesis-related disorder is osteoporosis deficiency, increased osteoporosis, fractures, weak bones, reduced bone mineral density (BMD), or any combination thereof. 10. The method according to item 1 of the patent application, wherein the SARM compound is represented by a structure having the chemical formula I ·· Q where G is oxygen or sulfur; X is a bond, oxygen, CH2, NH, selenium, PR, NO, or NR; 15 τ is 0Η, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR , NHCONHR, 20 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 91 200526202 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or the benzene ring to which Q is connected Together, it is a thick soil system represented by structural formula A, B or C; 5 R is alkyl, i-alkyl, di-iS alkyl, trihaloalkyl, ch2f, chf2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl or OH; and RACH3 , CH2F, CHF2, CF3, CH2CH3, or CF2CF3. 4. The method according to item 1 of the patent application scope, wherein the SARM compound is one of the compounds represented by 10 structures of formula II: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 Or SnR3; 15 Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R , OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the 92 200526202 benzene ring to which it is connected is a fused ring system represented by the formula Λ, B or C · R is an alkyl group, a substituted alkyl group, a di-substituted alkyl group, a tri-substituted alkyl group, CH2F, chf2, cf3, CF2CF3, aryl group, phenyl group, fluoro group, fluorene group, fluorene group, 5-chloro group, alkenyl group, or OH. ' 5. The method according to item 1 of the scope of patent application, wherein the compound is a compound represented by the structure of formula III: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 10 G is oxygen or sulfur; R ^ CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3; T is OH, OR, -NHCOCH3, or NHCOR; R is an alkyl group, a halogenated alkyl group, an alkyl group, a trihaloalkyl group, a trihaloalkyl group, ch2f, chf2 , CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, 15 gas, alkenyl or OH; A is a ring selected from the group consisting of: 93 200526202 B is a ring selected from the group: Where A and B cannot be a benzene ring at the same time; Z is N02, CN, COOH, COR, NHCOR or CONHR; 5 Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; (^ and (^ 2 Each independently is hydrogen, alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R , 10 OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, 15 NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR , NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and 20 W2 is nitrogen or NO. 94 200526202 6. The method of claim 1 in which the SARM compound is one of the compounds represented by the structure of formula IV: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 5 G is oxygen or sulfur; T is OH, OR, -NHCOCI ^ or NHCOR; R is alkyl, iS alkyl, di-alkyl, trihaloalkyl, CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, Bromine, chlorine, alkenyl or OH; 10 R1 is CH3, ch2f, chf2, CF3, CH2CH3 or CF2CF3; R2 is fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, gas, bromine, iodine, CN, N02, COR, COOH, 15 CONHR, CF3, SnR3; or R3 and its connected benzene ring to form a condensed ring system represented by the following structural formula; V7 or YZ is NO2, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; 95 200526202 Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, 5 COR, OCOR, OS02R, S02R, SR; or Q together with the benzene ring to which it is connected is a fused ring system represented by the structural formula A, B or C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 10 7. The method according to item 1 of the scope of patent application, wherein the SARM compound is a compound represented by a structure having a chemical formula V: V where R2 is fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, 15 NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR; R3 is fluorine , Gas, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or &amp; together with the benzene ring to which they are connected to form a condensed ring system represented by the following structural formula; 96 200526202 R is alkyl, alkyl, dihaloalkyl, triialkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl, or OH; 5 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR , OCONHR, CONHR, NHCSCH3, 10 NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the principal to which it is connected-starting from a structural formula A, B or C fused ring system; η is an integer from 1 to 4; and 15 m is an integer from 1 to 3. 8. The method according to item 丨 in the scope of patent application, wherein the compound is one of the compounds represented by the structure of Chemical Formula VI: 97 200526202 9. The method of claim 1 in the scope of patent application, wherein the SARM compound is one of the compounds represented by the structure of formula IX: 10. The method according to item 1 of the scope of patent application, wherein the SARM compound is a compound represented by five structures of chemical formula XI: 11. The method according to item 6 of the patent application, wherein the SARM compound is one of the compounds represented by the structure having the chemical formula XII: 10 where ρ is an integer between 2 and 5 and includes 2 and 5, the rest of the substituents are as defined in the above chemical formula IV. 12. The method of claim 7 in the scope of patent application, wherein the SARM compound is a compound represented by a structure having a chemical formula XV: XV 15 where ρ ′ is an integer between 1 and 4 and includes 1 and 4. The rest of the radicals are 98 200526202, as defined by the aforementioned chemical formula v. 13. The method of claim 1 in the scope of patent application, wherein the sarm compound is a compound represented by a structure having the chemical formula XVI: a compound:, 14. The method of claim 1, wherein the SARM compound is a compound represented by the structure of Chemical Formula XVIII: Where X is oxygen, CH2, NH, selenium, PR, NO or NR; 10 τ is 0Η, 〇R, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, Iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, 15 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q and the benzene ring to which it is connected is a condensed ring represented by structural formula A, B or C System; 99 200526202 Chlorine, alkenyl or OH; and r ^ ch3, ch2f, chf2, cf3, ch2ch3 or cf2cf3. 15. A method of increasing bone strength of an individual, comprising administering to the individual a selective androgen receptor modulator (SARM) compound, thereby increasing bone strength of an individual. 16. The method of claim 15 in which the subject has osteoporosis. 17. The method of claim 16 in which the osteoporosis is caused by hormones. 18. The method according to item 5 of the patent application, wherein the SARM compound is represented by a structure having the chemical formula I: Where G is oxygen or sulfur; X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 100 200526202 Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR , NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 5 NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is A fused ring system represented by structural formula A, B or C; 10R is alkyl, iS alkyl, di-alkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl, or OH ;and R ^ CH3, CH2F, chf2, CF3, CH2CH3, or CF2CF3. 19. The method according to claim 15 in which the SARM compound 15 is a compound represented by the structure of Chemical Formula II: II where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; 101 200526202 Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3 , NHS02R, OR, COR, OCOR, 50S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a condensed ring system represented by structural formula A, B or C; R is an alkyl group, a 1-substituted alkyl group, a 2-substituted alkyl group, a tri-substituted alkyl group, 10 CH2F, chf2, cf3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH. 20. The method of claim 15 in which the SARM compound is one of the compounds represented by the structure of Chemical Formula III: Where X is a bond, oxygen, CH〗, NH, Shixi, PR, NO or NR; G is oxygen or sulfur; R ^ ch3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR,- NHC〇CH3 or NHCOR; R is an alkyl group, a substituted alkyl group, a dihaloalkyl group, a tris-substituted alkyl group, ch2f, chf2, cf3, CF2CF3, aryl group, phenyl group, fluorine, iodine, bromine, 102 20 200526202 chlorine , Alkenyl or OH; A is a ring selected from the group consisting of: B is a ring selected from the group: Where A and B cannot be a benzene ring at the same time; Z is N02, CN, C00H, COR, NHC0R or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; Qi and Q2 are each independently Hydrogen, alkyl, fluorine, bromine, gas, 10 CF3, CN, CR3, SnR3, NR2, NHC0CH3, NHC0CF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently hydrogen, alkyl, fluorine, ethene, molybdenum, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, 200526202 NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR , NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R ^ SR, SCN, NCS, OCN, NCO; 5 Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 21. The method according to claim 15 in which the SARM compound is a compound represented by a structure having Chemical Formula IV: 10 where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, di-generation Alkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, 15 chlorine, alkenyl or OH; R ^ CH3, CH2F, CHF2, cf3, CH2CH3 or CF2CF3 ; R2 is fluorine, chlorine, bromine, moth, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN , NCO; 20 R3 is fluorine, chlorine, bromine, hard, CN, No2, COR, COOH, CONHR, CF3, SnR3; or R3 together with the benzene ring to which it is connected 104 200526202 A represented by the following structural formula Fused ring system Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; 5 Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OS02R, S02R, SR; or 10 benzene to which Q is connected The rings together are a fused ring system represented by the structural formula A, B or C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 22. The method of claim 15 in which the SAR] VHt complex 15 is a compound represented by a structure having the formula V: Where 105 V 200526202 R2 is fluorine, chlorine, bromine, iodine, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR; R3 is Fluorine, gas, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or together with the benzene ring to which it is connected, form a fused ring system represented by the following structural formula; Or 2 R is alkyl, alkyl, di-alkyl, tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, 10 gas, alkenyl or OH; Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, 15 NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OSO2R, SO2R, SR; or the benzene ring to which Q is connected is a fused ring system represented by the structural formula A, B or C; A 20 η is an integer from 1 to 4; and 106 200526202 m is an integer from 1 to 3. 23. The method according to claim 15 in which the SARM compound is a compound represented by the structure of Chemical Formula VI: nmcoch3 5 24. The method according to item 15 of the scope of patent application, wherein the SARM compound is a compound represented by a structure having Chemical Formula IX: 25. The method according to item 15 of the application, wherein the SARM compound is a compound represented by the structure of Chemical Formula XI: 26. The method of claim 21, wherein the SARM compound is a compound represented by a structure having the chemical formula XII: 107 XII 200526202 where P is a number between 2 and 5 and includes 2 and 5, and the rest of the substituents are as defined in Chemical Formula IV above. 27_ The method according to item 22 of the application for a patent, wherein the sarm compound is a compound represented by a structure having the chemical formula XV: XV 5 where P is an integer between 1 and 4 and includes 丨 and 4. The rest of the substituents are as defined by the above-mentioned chemical formula V. 28. The method of claim 15 in which the compound is a compound represented by the structure of Chemical Formula XVI: 29. The method of claim 15 in the scope of patent application, wherein the 8-person ruler compound is a compound represented by a structure having the formula XVIII: Where 15 X is oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 108 200526202 Y is CF3, fluorine , Iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, 5 NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q together with the benzene ring to which it is connected is a thick one represented by structural formula A, B or C Ring system; 10 15 ABCR is alkyl, alkyl, di-alkyl, trihaloalkyl, alkyl, ethyl, ethyl, aryl, phenyl, gas, molybdenum, molybdenum, chlorine, alkenyl, or OH; And R ^ CH3, ch2f, chf2, cf3, Ch2CH3, or CF2CF3. 30. A method of increasing an individual's method, the method comprising administering to the individual a selective pure hormone U㈣ 子 (certificate compound), thereby increasing a bone of a body 31. 30. Method of pineal disease. Quality. 'Where the individual has osteoporosis. 32. For example, the method of applying for rhyme peritoneum, wherein the osteoporosis is caused by hormones. 33. Such as the scope of patent application No. 30. The quality of the item, wherein the bone is cortical bone 34. The method according to item 30 of the patent application, wherein the bone is trabecular bone or 109 20 200526202 cancellous bone. 35. The method of claim 30 in the scope of patent application, wherein the 8-member 1 ^ 4 compound is represented by a structure of formula I: Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is No2, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; 10 15 Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which they are connected Is a fused ring system represented by the structural formula A, B or C; A R is alkyl, i-alkyl, dihaloalkyl, tri-functional alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, 200526202 chlorine, alkenyl or OH; and R ^ CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3. 36. The method of claim 30, wherein the compound is a compound represented by the structure of Chemical Formula II: 5 II Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 Or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, 10 NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 〇02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected are a single structure 15 fused ring system represented by formula A, B or C; R is an alkyl group, a 12-alkyl group, a di-alkyl group, a tri-alkyl group, ch2f, chf2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl or OH. 111 200526202 37. The method according to item 30 of the patent application, wherein the Sarm compound is one of the compounds represented by the structure having the formula III: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 5 G is oxygen or sulfur; RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, functional alkyl, dihaloalkyl, trihaloalkyl, ch2f, chf2, CF3, CF2CF3, aromatic Group, phenyl, fluorine, iodine, bromine, 10 gas, alkenyl or OH; A is a ring selected from the group consisting of: 15 where A and B cannot be a benzene ring at the same time; Z is No. 02, CN, COOH, COR, NHCOR or CONHR; 112 200526202 Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; Qi and Q2 are each independently hydrogen, alkyl, fluorine, moth, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, 5 NHCSCH3, NHCSCF3, NHCSR, NHS02CH3 , NHS02R, OR, COR, OCOR, OS02R, S02R, SR, SCN, NCS, OCN, NCO, .HN · "/ ΗΪ Or Q4 Q3 and Q4 are each independently hydrogen, alkyl, fluorine, iodine, bromine, chlorine, 10 CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3 , NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN, NCO; 15 wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 38. The method according to item 30 of the application for a patent, wherein the compound ^ 1 is a compound represented by a structure having the formula IV: 20 where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 113 200526202 G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, ii-alkyl , Dihaloalkyl, trifunctional alkyl, CH2F, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, bromine, 5 chlorine, alkenyl, or OH; R ^ CH3, CH2F, CHF2, CF3 , CH2CH3 or CF2CF3; R2 is fluorine, gas, bromine, carbon, CH3, CF3, OH, CN, No2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR , SCN, NCS, OCN, NCO; 10 R3 is fluorine, chlorine, bromine, polonium, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form a structure by the following formula Representative fused ring system; Z is N02, CN, COR, COOH or CONHR; 15 Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, 20 COR, OCOR, OSO2R, SO2R, SR; or Q connected to their household weight The benzene rings together are a fused ring system represented by the structural formula A, B or C; 114 200526202 η is an integer from 1 to 4; and m is an integer from 1 to 3. 39. If the method of claiming item 3G of the patent is declared, wherein the conforming compound is represented by a structure having the chemical formula V—compound: Where R2 is fluorine, gas, bromine, iodine, ch3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, 100R, NH2, NHR, NR2, SR; R3 is fluorine , Chlorine, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or &amp; together with the benzene ring to which they are attached, form a condensed ring system represented by the following structural formula; Or R is an alkyl group, a halogenated alkyl group, a di-substituted alkyl group, a tri-substituted alkyl group, CH2F, chf2, CF3, CF2CF3, an aryl group, a phenyl group, a fluorine group, a hard group, a molybdenum group, an alkenyl group, or an OH group; 115 200526202 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN or SnR3; Q is thallium, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3 , SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, 5 NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q to which they are connected The benzene ring together is a fused ring system represented by the structural formula A, B or C; 10 η is an integer from 1 to 4; and m is an integer from 1 to 3. 40. The method of claim 30, wherein the SARM compound is a compound represented by a structure having the formula VI: 15 41. If the method for applying for item 3G is applied, the SARM compound is a compound represented by the structure of Chemical Formula IX: NC 116 200526202 42. The method according to claim 30, wherein the SARM compound is one of the compounds represented by the structure having the chemical formula XI: 43. The method of claim 38, wherein the SARM compound 5 is a compound represented by a structure having the chemical formula XII: Wherein P is an integer between 2 and 5 and includes 2 and 5, the rest of the substituents are as defined in the above chemical formula IV. 44. The method of claim 39, wherein the SARM compound 10 is a compound represented by a structure having the chemical formula XV: Wherein P 'is an integer between 1 and 4 and includes 1 and 4, the remaining substituents are as defined by the above-mentioned chemical formula V. 45. The method of claim 30, wherein the SARM compound 15 is a compound represented by a structure having the chemical formula XVI: 117 200526202 46. The method according to claim 30, wherein the SARM compound is a compound represented by the structure of Chemical Formula XVIII: 7 5 where X is oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine , Bromine, gas, CN, CR3 or SnR3; 10 Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHC0CH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS〇2R, S〇2R, SR; or Q to which it is connected The benzene rings together are a fused ring system represented by the formula A, B or C; R is alkyl, haloalkyl, di-alkyl, trihaloalkyl, 118 200526202 ch2f, chf2, cf3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl, or OH; and Ri is CH3, CH2F, CHF2, cf3, ch2ch3, or cf2cf3. 47. A method of reducing fat mass in a body, the method comprising administering to the individual a selective androgen receptor modulator (SARM) compound, thereby reducing fat mass in a body. 48. The method of claim 47, wherein the individual suffers from a hormonal imbalance, disorder or disease. 49. The method of claim 47, wherein the individual stops menstruation. 10 50. The method of claim 47, wherein the SARM compound is represented by a structure of formula I: Where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO, or NR; 15 T is OH, OR, -NHCOCH3, or NHCOR; Z is N02, CN, COOH, COR, NHCOR Or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, 20 NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, 119 200526202 S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which they are connected Is a fused ring system represented by the structural formula A, B or C; R is alkyl, i-alkyl, di-alkyl, tri-i alkyl, ch2f, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl, or OH; and RACH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3. 51. The method of claim 47, wherein the SARM compound is a compound represented by the structure of Chemical Formula II: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 Or SnR3; Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and its connected benzene ring is a 120 200526202 fused ring system represented by the structural formula A, B or C; A R is alkyl, i-alkyl, di-i alkyl, tri-i alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, 5-chloro, alkenyl or OH. 52. The method of claim 47, wherein the SARM compound is a compound represented by the structure of Chemical Formula III: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 10 15 G is oxygen or sulfur; RACH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, ii-alkyl, di-i-alkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3 , Aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH; A is a ring selected from the group consisting of: 121 200526202 B is a ring selected from the group: A and B cannot be a benzene ring at the same time; Z is No. 02, CN, COOH, COR, NHCOR, or CONHR; 5 Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3, or SnR3; (^ and 仏Each independently is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R , 10 OR, COR, OCOR, OS02R, S〇2R, SR, SCN, NCS, OCN, NCO, Q3 and Q4 are each independently argon, alkyl, fluorine, moth, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOC3, 15 NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3 , NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and 20 W2 is nitrogen or NO. 122 200526202 53_ The method according to item 47 of the patent application, wherein the SARM compound is a compound represented by a structure having Chemical Formula IV: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 5 G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, dihaloalkyl , Trihaloalkyl, CH2F, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl or OH;! 0 Ri is ch3, CH2F, CHF2, cf3, CH2CH3 or CF2CF3; R2 is Fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, chlorine, bromine, iodine, CN, N02, COR, COOH, 15 CONHR, CF3, S11R3; or R3 and the benzene ring connected to it form a condensed ring system represented by the following structural formula; Z is No2, CN, COR, COOH or CONHR; y is cf3, fluorine, desert, gas, moth, CN4SnR3; 123 200526202 Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, cf3, CN, CR3 , SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q is connected to it The stupid ring together is a fused ring system represented by the structural formula A, B or C; A B c η is an integer from 1 to 4; and m is an integer from 1 to 3. 10 54. The method according to item 47 of the application, wherein the eight-eight-foot dish compound is one of the compounds represented by the structure having the chemical formula V: Where R2 is fluorine, gas, molybdenum, iodine, ctj3, CF3, 0H, CN, No2, 15M ™™ 3, NHC0CFr NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR ; R3 is fluorine, gas, desert, iodine, CN, No2, coR, C00H, CONHR, CF3, SnR3; X3 and the benzene ring connected to it together to form a condensed ring represented by the following structural formula System; 124 200526202 Or γ R is an alkyl group, a functional alkyl group, a di-iS alkyl group, a tri-i alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH; 5 Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, 10 NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q is connected to it Benzene ring together is a fused ring system represented by the structural formula A, B or C; NH 乂 0 A 15 η is an integer from 1 to 4; and m is an integer from 1 to 3. 55. The method of claim 47 in the scope of Shen Qing's patent, wherein the SARM compound is a compound represented by the structure of Chemical Formula VI: NHC0CH3 VI 125 0 200526202 56. The method according to item 47 of the patent application, wherein the SARM compound is one of the compounds represented by the structure having the chemical formula IX: 57. The method of claim 47, wherein the SARM compound 5 is a compound represented by the structure of Chemical Formula XI: 58. The method of claim 53, wherein the SARM compound is a compound represented by a structure having the chemical formula XII: XII 10 where p is an integer between 2 and 5 and includes 2 and 5, the rest of the substituents are as defined in the above chemical formula IV. 59. The method of claim 54, wherein the SARM compound is a compound represented by a structure having the chemical formula XV: 126 200526202 ′, where P is an integer between 1 and 4—including 丄 and 彳, the rest of the substituents are as defined by the above-mentioned chemical formula V. 60. The method according to claim 47, wherein the compound is represented by a structure having the chemical formula XVI-compound:, 61. The method of claim 47 in the patent scope, wherein the SARM compound is a compound represented by a structure having the chemical formula XVIII: Where 10 X is oxygen, CH2, NH, Shixi, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, Iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, 15 NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring to which it is connected is a fused ring system represented by structural formula A, B or C; 127 200526202 A b R is alkyl, i-alkyl, di-alkyl, trihaloalkyl, CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, fluoro, ethene, bromine, chlorine, alkenyl or OH; and Ri is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3. 62. A method of increasing the muscle mass of an individual, the method comprising administering to the individual a selective androgen receptor modulator (SARM) compound, thereby increasing the muscle mass of an individual. 63. The method of claim 62, wherein the individual has a hormonal imbalance, disorder or disease. 64. The method according to item 62 of the patent application scope, wherein the individual ceases menstruation. 65. The method according to item 62 of the application for a patent, wherein the §8-foot] 4 compound is represented by a structure of formula I: 15 where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO, or NR; T is OH, OR, -NHCOCH3, or NHCOR; Z is N02, CN, COOH, COR, NHCOR Or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3 or SnR3; 128 200526202 Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 5 〇S02R, S02R, SR, SCN, NCS, OCN, NC〇; or the benzene to which Q is connected The rings together are a fused ring system represented by the structural formula A, B or C; R is alkyl, alkynyl, dihalo, dihalo, dihalo, ch2f, chf2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl, or OH; and R々CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3 〇66 · As in the method of claim 62, wherein the SARM compound is one of the compounds represented by the structure of formula II: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 * SnR3; 15 II Q is alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, 129 200526202 NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R , OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q together with the benzene ring to which it is connected is a fused ring system represented by structural formula A, B or C; NH ^ 0 NH 乂 0 A R is an alkyl group, a halogenated alkyl group, a dihalogenated alkyl group, a trihalogenated alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl group, phenyl group, fluorine, iodine, bromine, 10 gas, alkenyl group or OH. 67. The method of claim 62, wherein the SARM compound is a compound represented by the structure of Chemical Formula III: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR 15 G is oxygen or sulfur; RACH3, ch2f, chf2, cf3, ch2ch3 or cf2cf3 T is oh, OR, -NHCOCH3 or NHCOR; R Alkenyl, alkynyl, di-alkynyl, di-alkynyl, ch2f, chf2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, alkenyl or OH; 130 20 200526202 A Is a ring selected from the group: B is a ring selected from the group: 5 where A and B cannot be a benzene ring at the same time; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; (^ and 仏 are independent of each other Ground is hydrogen, alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, 10 NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO, 15 Q3 and Q4 are each independently hydrogen, alkyl, fluorine, moth, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, 131 200526202 NHCSCH3, NHCSCF3 , NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R or SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and 5 W2 is nitrogen or NO. 68. The method according to item 62 of the patent application, wherein the SARM compound is a compound represented by a structure having Chemical Formula IV: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; 10 G is oxygen or sulfur; T is OH, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, dihaloalkyl , Tri-alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH; 15 Rl is CH3, CH2F, chf2, cf3, ch2ch3 or CF2CF3; R2 Fluorine, chlorine, bromine, iodine, CH3, CF3, OH, CN, N02, nhcoch3, Lico CF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, gas, desert, iodine, CN, N02, COR, COOH, 20 CONHR, CF3, SnR3; or R3 and the benzene ring connected to it form a thick compound represented by the following structural formula Ring system; 200526202 Q or z O- ^ YYZ is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, angstrom, bromine, chlorine, CF3 , CN, CR3, 5 SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structural formula A ,; 6 or (^; n is an integer from 1 to 4; and m is an integer from 1 to 3. 10 69. The method of claim 62, wherein the SARM compound is a compound represented by a structure having a chemical formula V: Where R2 is fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, 133 200526202 NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR; R3 is fluorine , Chlorine, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, SnR3; or R3 and the benzene ring to which it is connected form a fused ring system represented by the following structural formula; R is alkyl, haloalkyl, di-substituted alkyl, tri-substituted alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, hard, bromine, gas, alkenyl, or OH; 10 Z is No. 02, CN, COR, COOH, or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN, or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, gas, CF3, CN, CR3, SnR3 , NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, 15 NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene to which it is connected The rings together are a fused ring system represented by the structural formula A, B or C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 20 200526202 70. The method according to item 62 of the patent application, wherein the SARM compound is one of the compounds represented by the structure of Chemical Formula VI: nmcoch3 71. The method according to item 62 of the patent application, wherein the SARM compound 5 is a compound represented by the structure of Formula IX: F 72. The method of claim 62, wherein the SARM compound is a compound represented by a structure having chemical formula XI: CI 10 73. The method of claim 68, wherein the SARM compound is a compound represented by a structure having the chemical formula XII: (F) P where p is an integer between 2 and 5 and includes 2 and 5, and the rest is 135 200526202. The radical is as defined by the above formula IV. &Lt; Method, wherein the SARM compound is represented by One of the compounds represented by the structure of chemical formula XV 74. Such as the scope of application for patent No. 69 1 疋. 5 XV where P ’is between 1 and 4 ^ an integer and includes 1 and 4, the rest of the substituents are as defined by the above chemical formula V If, for example, the scope of the patent application No. 62, its nacal compound is a compound represented by a structure having the chemical formula XVI: 10 76. The method according to item 62 of the application, wherein the SAR] yHb compound is a compound represented by the structure of Chemical Formula XVIII: X is oxygen, CH2, NH, selenium, PR, NO or NR; Where T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3 or SnR3; 136 15 200526202 Q is alkane Base, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR; or Q and the benzene ring to which it is connected is a fused ring system represented by the structural formula A, B or C; NH〆〇NH / 0 R is an alkyl group, a halogenated alkyl group, a di-substituted alkyl group, a tri-substituted alkyl group, CH2F, chf2, CF3, CF2CF3, aryl group, phenyl group, fluorine, ethene, molybdenum, 1015 gas, dilute group, or OH; and R々CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3. 77. A method of increasing the lean muscle mass of an individual, the method comprising administering a selective androgen receptor modulator (SARM) compound to 4 individuals, thereby increasing the lean muscle mass of an individual. 78. The method of claim 77, wherein the individual has a hormonal imbalance, disorder or disease. 79. If you apply for the method of item _77, the cap face will stop. 80. The method of claim 77, wherein the surface-forming compound is represented by a structure having the chemical formula I: 137 20 200526202 where G is oxygen or sulfur; X is one-bond, oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR , NHCOR, or CONHR; 5 Y is CF3, fluorine, iodine, bromine, chlorine, CN, CR3, or SnR3; Q is alkyl, fluorine, moth, bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, 10S02R, SR, SCN, NCS, OCN, NCO; or the benzene to which Q is connected The rings together are a fused ring system represented by the structural formula A, B or C; ABCR is an alkyl group, a 1-substituted alkyl group, a di-substituted alkyl group, a tri-substituted alkyl group, CH2F, CHF2, cf3, cf2cf3, aryl, phenyl, fluorine, iodine, molybdenum, 15 chlorine, alkenyl or OH; And RACH3, CH2F, chf2, cf3, ch2ch3, or cf2cf3. 81. The method according to item 77 of the application, wherein the 8 persons are represented by a compound represented by the structure of formula II as a compound: II 200526202 where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; Z is N02, CN, COOH, COR, NHCOR or CONHR; Y is CF3, fluorine, iodine, bromine, chlorine, CN , CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, 5 NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3 , NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO; or Q and the benzene ring to which it is connected is a 10 fused ring system represented by the structural formula A, B or C; R is an alkyl group, an iS alkyl group, a dialkyl group, a trifunctional alkyl group, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, gas, dilute group, or OH. 15 82. The method according to item 77 of the application, wherein the SARM compound is a compound represented by the structure of Chemical Formula III: Where X is a bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; 20 Ri is ch3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; 139 200526202 T is OH, OR, -NHCOCH3 or NHCOR; R is an alkyl group, a 1-substituted alkyl group, a di-substituted alkyl group, a trihalogenated alkyl group, CH2F, chf2, CF3, CF2CF3, aryl group, phenyl group, fluorine, iodine, bromine, chlorine, olefin Or OH; A is a ring selected from the group: B is a ring selected from the group: A and B cannot be a benzene ring at the same time; ίο Z is N02, CN, COOH, COR, NHCOR, or CONHR; Y is CF3, fluorine, iodine, bromine, gas, CN, CR3, or SnR3; (^ and (^ are each independently hydrogen, alkyl, fluorine, iodine , Bromine, gas, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, 15 NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, 0S02R, S02R, SR, SCN, NCS, OCN, NCO, 140 200526202 Q3 and Q4 are each independently hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OR, COR, OCOR, OS02R, S02R ^ SR, SCN, NCS, OCN, NCO; Wi is oxygen, NH, NR, NO or sulfur; and W2 is nitrogen or NO. 83. The method according to claim 77, wherein the SARM compound is a compound represented by a structure having Chemical Formula IV: Where X is a single bond, oxygen, CH2, NH, selenium, PR, NO or NR; G is oxygen or sulfur; 15 T is 0H, OR, -NHCOCH3 or NHCOR; R is alkyl, haloalkyl, dihaloalkane Base, tri! I-substituted alkyl, ch2f, chf2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, chlorine, alkenyl or OH; R ^ CH3, CH2F, CHF2, CF3, CH2CH3 or CF2CF3; Ruler 2 is fluorine, gas, bromine, iodine, CH3, CF3, OH, CN, N02, 20 200526202, COCO3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, NR2, SR, SCN, NCS, OCN, NCO; R3 is fluorine, chlorine, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or &amp; together with the benzene ring to which it is connected, it forms a thick compound represented by the following structural formula: Ring system Z is N02, CN, COR, COOH or CONHR; Y is CF3, fluorine, bromine, chlorine, iodine, CN or SnR3; Q is hydrogen, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, 10 SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OS02R, S02R, SR; or the benzene ring to which Q is connected Together they are a fused ring system represented by structural formula A, B or C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 84. The method according to item 77 of the patent application, wherein the SARM compound is one of the compounds represented by the structure having the chemical formula V: 200526202 〇Ηλ OH Υ V OR, ΝΗ2, NHR, NR2, SR; R3 is fluorine, gas, bromine, iodine, CN, N02, COR, COOH, CONHR, CF3, S11R3; or Rs together with the benzene ring to which they are connected is formed by the following structural formula Representative fused ring system; 10 R is alkyl, haloalkyl, di-i-alkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, fluorine, iodine, bromine, gas, alkenyl or OH; Z is N02, CN, COR, COOH, or CONHR; Y is CF3, fluorine, bromine, gas, iodine, CN, or SnR3; 15 Q is pyrene, alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2 NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHS02CH3, NHS02R, OH, OR, COR, OCOR, OS02R, S02R, SR; or Q and the 200526202 benzene ring to which they are connected is one Fused ring system represented by structural formula A, B or C; η is an integer from 1 to 4; and m is an integer from 1 to 3. 5 85. The method according to item 77 of the claims, wherein the SARM compound is One of the compounds represented by the structure of Formula VI: 86. The method according to claim 77, wherein the SARM compound is a compound represented by the structure of Chemical Formula IX: 87. The method according to claim 77, wherein the SARM compound is a compound represented by a structure having Chemical Formula XI: 144 200526202 88. The method according to claim 83, wherein the SARM compound is one of the compounds represented by the structure having the formula XII: Wherein P is an integer between 2 and 5 and includes 2 and 5, the rest of the radical 5 is as defined in the above chemical formula IV. 89. The method according to claim 84, wherein the SARM compound is a compound represented by a structure having the chemical formula XV: Wherein P 'is an integer between 1 and 4 and includes 1 and 4, the rest of the 10-based radicals are as defined by the above-mentioned chemical formula V. 90. The method of claim 77, wherein the SARM compound is a compound represented by a structure having the chemical formula XVI: 91. The method according to claim 77, wherein the SARM compound 15 is a compound represented by the structure of Chemical Formula XVIII: 7 145 200526202 where X is oxygen, CH2, NH, selenium, PR, NO or NR; T is OH, OR, -NHCOCH3 or NHCOR; Z is N02, CN, COOH, COR, NHCOR or CONHR; 5 Y is CF3, fluorine , Iodine, bromine, chlorine, CN, CR3 or SnR3; Q is alkyl, fluorine, iodine, bromine, chlorine, CF3, CN, CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, KHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, LiS02CH3, NHS02R, 〇R, COR, OCOR, 0 〇〇〇〇2R, S〇2R 'SR; or 卩 and the benzene ring to which it is connected-from-by the formula A, B or C fused ring system; R is an alkyl group, an i-alkyl group, a di-alkyl group, a tri-alkyl group, CH2F, chf2, cf3, CF2CF3, aryl group, phenyl group, gas group, molybdenum group, molybdenum group, 15 Gas, alkenyl or OH; and Ri is CH3, CH, F, 2 CHF2, cf3, CH2CH3 or CF2CF3. 146